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Snyder, Blair, M.S., May 2013           Community Health 
Examining the Impact of Hepatitis C in Montana: A Descriptive Case Study 
Chairperson: Dr. Annie Sondag 
The purpose of this study was to gather information about how Hepatitis C (HCV) affects 
Montanans. Montana specific information was collected about HCV transmission; factors 
influencing transmission; physical, social and psychological effects of having HCV and 
undergoing treatment; barriers to prevention and treatment; current available resources to those 
infected with HCV and ways to improve prevention and treatment. Secondary data consisted of a 
comprehensive literature review to describe the above factors and epidemiological information. 
Primary data was collected through key informant interviews and summary reports completed by 
people living with HCV. The findings suggest that HCV is primarily transmitted through the use 
of contaminated needles to inject drugs in Montana; Montana Law prohibits needle exchange 
programs. Although the literature and key informants confirmed that poverty is an environmental 
factor that contributes to the spread of HCV, HCV positive participants did not concur; therefore, 
the relationship between poverty and the spread of HCV remains undefined. Other 
environmental factors that were found to significantly contribute to the spread of HCV in 
Montana are the lack of access to clean needles, lack of public education and awareness and the 
prison and jail systems. The physical, social and psychological effects of not only having HCV, 
but being treated for HCV, were found to be tremendous. Treatment costs, lack of knowledge, 
difficulty of treatment, lack of access to treatment, the slow progression of the infection, having 
to be clean and sober before starting treatment and the stigma and lack of knowledge among 
physicians were all found to be large barriers to seeking treatment. Barriers to prevention 
included the lack of education and funding, stigma, and having few prevention options. 
Increasing media, awareness, and education were highlighted as the best ways to improve 
prevention. In order to improve treatment, it is necessary to not only decrease the cost, but also 
make it more available throughout the state of Montana. The findings from this study will be 
used by the Montana Department of Public Health and Human Services to increase awareness of 
how HCV impacts Montana residents.  
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CHAPTER ONE 
INTRODUCTION 
 
Although seldom thought to be a sizeable problem among Americans, the hepatitis C virus 
(HCV) is the most widespread chronic bloodborne infection in the United States (Centers for 
Disease Control and Prevention [CDC], 2011). Specifically, an estimated 2.7-3.9 million people 
in the United States, 1.0%-1.5% of the population, are living with HCV (Smith et al., 2012).  
Upon its discovery in 1988, HCV was first thought to be an infection of minor importance; 
however, it is now of global significance due to its extensive effects (Lavanchy, 2011). The 
World Health Organization estimates that roughly 3% of the world’s population is infected with 
HCV. Moreover, there are more than 170 million carriers who are at risk of developing cirrhosis 
and/or liver cancer (World Health Organization [WHO], 2002). Countries with the highest rates 
of chronic infection are Egypt (22%), Pakistan (4.8%) and China (3.2%). The dominant mode of 
transmission in these countries is unsafe injections using contaminated equipment (WHO, 
2012b). 
 
HCV is primarily transmitted through exposure to infectious blood. Transmission can occur 
through a variety of pathways: through receipt of contaminated blood transfusions, blood 
products and organ transplants; injections given with contaminated syringes and needle-stick 
injuries in healthcare settings; injection drug use; or being born to an HCV-infected mother 
(WHO, 2012b). HCV can potentially be transmitted through sex with an infected person or 
through sharing of personal items contaminated with infectious blood, but is unlikely. HCV 
cannot be transmitted though breast milk, food or water or by casual contact such as hugging, 
kissing and sharing food or drinks with an infected individual (WHO, 2012b).  
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Hepatitis is a universal term indicating inflammation of the liver and can be caused by a variety 
of different viruses such as hepatitis A, B, C, D and E (WHO, 2002). HCV is an RNA virus that 
has 6 genotypes and more than 50 subtypes (NIH Consensus Development Program [NCDP], 
2002). There is currently no vaccine for HCV; however, highly effective treatments do exist and 
HCV is curable using antivirals (WHO, 2012b). The majority of people infected with HCV are 
asymptomatic; therefore, infected individuals may only seek treatment when complications occur 
as part of the natural progression of untreated infection (Denniston, Klevens, McQuillan & Jiles, 
2012). Although they may be asymptomatic, infected individuals can still serve as a source of 
transmission to others.  Moreover, they are still at risk for chronic liver disease or other HCV-
related chronic diseases even decades after infection (CDC, 2011).  If those infected with HCV 
are left untreated, they may develop hepatic fibrosis, cirrhosis, and hepatocellular carcinoma 
(Younossi, Kallman & Kincaid, 2007).  
 
There are two types of HCV infection: acute and chronic. There are standard definitions and 
clinical descriptions of both acute and chronic HCV. CDC defines acute HCV as a short-term 
illness that occurs within the first 6 months after someone is exposed to HCV (CDC, 2010a). In 
contrast, the Council of State and Territorial Epidemiologists (CSTE) defines the clinical 
description of acute HCV infection as an acute illness with a discrete onset of any sign or 
symptom consistent with acute viral hepatitis and either a) jaundice, or b) elevated serum alanine 
aminotransferase (ALT) levels > 400 IU/L. Examples of symptoms are: fever, headache, malaise, 
anorexia, nausea, vomiting, diarrhea and abdominal pain (CSTE, 2012).  Research has shown 
that 75-85% of acute HCV cases develop into chronic HCV infection (CDC, 2011). For the 
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purposes of this research, the first and most standard definition of acute hepatitis C will be used 
when referring to acute hepatitis C.  
 
Like acute HCV, there are two ways to define chronic HCV. The CDC’s standard definition of 
chronic HCV is a long-term illness that occurs when the hepatitis C virus remains in a person’s 
body for six months or more. In comparison, the CDC laboratory criteria for chronic HCV is 
defined by meeting one or more of the following criteria: testing positive for anti-HCV by 
enzyme immunoassay (EIA) verified by at least one additional more specific assay or testing 
positive using a nucleic acid or HCV-RIBA (recombinant immunoblot assay) test (CDC, 2012a).  
For the purposes of this research, the first and standard definition of chronic hepatitis C will be 
used when referring to chronic hepatitis C. 
 
In 1998, the highest prevalence of HCV was documented among persons with considerable or 
recurrent direct percutaneous exposures, such as people who inject drugs (PWID), those who 
received blood from infected donors, and persons with hemophilia (Smith et al., 2012). Prior to 
1965, the estimated incidence of HCV infection (then known as Non A-Non B hepatitis) was low 
(18 cases per 100,000 population). Nevertheless, the incidence of HCV infection increased into 
the 1980’s and remained high (130 cases per 100,000 population), with an average of 230,000 
infections per year during that decade (Smith et al., 2012). Then known as Non A- Non B 
hepatitis, HCV was identified in 1988. Consequently, assays for testing blood were developed 
and licensed by 1992. During the years 1992-2004, the number of reported cases of new HCV 
infection decreased 78.4% and during 1999-2008, HCV prevalence among first time blood 
donors decreased 53% (Smith et al., 2012). A small part of this decline can be attributed to a 
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decrease in cases among PWID and the use of safer injection practices; however, the bulk of the 
decline was most likely related to HCV infection saturation of the PWID population. HCV 
incidence has been stable since 2004.  In 2010, the number of newly acquired infections was 
17,000 (Smith et al., 2012).   
 
The CDC states that baby boomers are five times more likely than other American adults to be 
infected with the disease. Additionally, more than 75% of American adults infected with HCV 
are baby boomers. As of August 2012, the CDC recommended that all baby boomers 
(individuals born between 1945-1965) get tested for HCV (CDC, 2012b). This is because testing 
for HCV was not developed until July 1992 so any person receiving a blood transfusion, solid 
organ transplant or long-term hemodialysis treatment before this time could have been at risk for 
contracting HCV. CDC also recommends HCV testing for people who have ever injected drugs, 
are living with HIV, have signs and symptoms of liver disease or were born to mothers who have 
hepatitis C.  As a result of CDC’s new, expanded recommendations, it is likely that the numbers 
of those infected with HCV will increase dramatically (CDC, 2012b).  
 
There is a growing prevalence of HCV in rural communities (CDC, 2010c). With an increase in 
prevalence, there is also a greater demand for prevention programs. Furthermore, individuals 
living in rural areas are more difficult to reach with prevention efforts and often have limited 
access to care (Rossaro, 2003). Unfortunately, because of lack of information about HCV in rural 
states like Montana, planning for HCV prevention and treatment is difficult.  
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Purpose of the Study 
 
The purpose of this study was to fill gaps in information about HCV in Montana by providing 
Montana specific information about HCV transmission; factors influencing transmission; 
epidemiological data; physical, social and psychological effects of HCV diagnosis and treatment; 
barriers to prevention and treatment, and current available resources to those presently infected 
with HCV. The Montana Department of Public Health and Human Services (MTDPHHS) and 
local health departments will use information from this study to help increase awareness of how 
HCV impacts Montana residents.  Information from this study could lead to better and more 
optimally targeted prevention efforts.  
 
Statement of the Problem 
 
Every year, 3-4 million people worldwide are infected with HCV. About 150 million people are 
chronically infected and at risk for developing cirrhosis and/or liver cancer.  Moreover, more 
than 350,000 people die from hepatitis C-related liver disease annually (WHO, 2012b).  
Individuals infected with HCV report poor health-related quality of life (HRQL) and experience 
psychological and somatic problems in relation to the infection and the treatment (Evon et al., 
2012). Historically, the MTDPHHS has collected testing data regarding HCV infection; 
however, this data has not been systematically entered into a database and analyzed. 
Furthermore, there are no studies in Montana that provide any data about HCV. This lack of 
compiled information makes it difficult to offer effective prevention and treatment services that 
target those most in need. 
	  
	  
6	  
Significance of the Study 
 
The information gathered from this study will be used by the MTDPHHS and local health 
departments to help increase awareness of how HCV impacts Montana residents. Results from 
this study will help Montana’s health professionals become more knowledgeable about the 
behaviors contributing to HCV infection, the factors influencing those behaviors, the physical, 
social and psychological effects of HCV diagnosis and treatment, the barriers to prevention and 
treatment and current available resources to those presently infected with HCV in Montana.  
Additionally, epidemiological data about HCV in Montana will help distinguish the populations 
of people most affected by HCV. This knowledge could lead to better and more optimally 
targeted prevention efforts. 
The PRECEDE-PROCEED Logic Model 
 
Research questions were designed to gather information that is specific to HCV infection in 
Montana; they are based in part on phases two through five of the PRECEDE-PROCEED logic 
model. The PRECEDE-PROCEED logic model is used to provide a road map for designing 
health education and health promotion programs (Rimer & Glanz, 2005). The PRECEDE-
PROCEED logic model consists of two approaches. The PRECEDE model is used to ensure 
comprehensive assessment and planning phases, while the PROCEED model is used to address 
the implementation and evaluation components of health education (Gilmore & Campbell, 2005, 
p. 22). PRECEDE is an acronym that stands for Predisposing, Reinforcing, and Enabling 
Constructs in Educational/ecological Diagnosis and Evaluation. PROCEED is an acronym that 
stands for Policy, Regulatory and Organizational Constructs in Educational and Environmental 
Development (Gilmore & Campbell, 2005, p. 22). This logic model was developed in the 1970s 
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and it assumes that an educational diagnosis is needed to design a health promotion intervention, 
just as a medical diagnosis is needed to design a treatment plan (Rimer & Glanz, 2005).  
 
The PRECEDE-PROCEED model consists of nine phases; however, the research questions used 
in this study are based in part on phases two-five. Phase two is entitled “Epidemiological 
Assessment” and it involves utilizing epidemiological data to identify the health problems of 
interest (Rimer & Glanz, 2005). In the case of this study, the health problem is HCV in Montana.  
Phase three is called “Behavioral/Environmental Assessment” and involves identifying the 
behavioral and environmental factors that contribute to the health problem of interest. Phase four 
is entitled “Educational/ Ecological Assessment” and involves identifying predisposing, enabling 
and reinforcing (PER) factors related to the health problem. Predisposing factors facilitate or 
hinder motivation for change (Gilmore & Campbell, 2005, p. 20). Examples of predisposing 
factors are: knowledge, attitude, beliefs, perceptions, age, and gender. Enabling factors are 
“those skills, resources or barriers that can help or hinder the desired behavioral changes as well 
as environmental changes” (Gilmore & Campbell, 2005, p. 20). Reinforcing factors are “the 
rewards received and the feedback the learner receives from others following adoption of a 
behavior” (Gilmore & Campbell, 2005, p. 20). Examples of reinforcing factors could be social 
acceptance, significant people, family or organizations (Rimer & Glanz, 2005). The final step, 
step five, is entitled “Administrative/ Policy Assessment” and involves identifying policies, 
resources, and circumstances in the program’s context that may help or hinder implementation 
(Rimer & Glanz, 2005).  
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The research questions, specific to Montana, are as follows: 
1. What is the epidemiology of HCV? 
a. What is the incidence and prevalence of HCV? 
b. What are the demographic characteristics of those infected with HCV? 
2. What are the behaviors and environmental factors that contribute to infection with HCV 
in Montana and what factors influence those behaviors? 
3. What are the physical, social and psychological effects of HCV diagnosis? 
4. What are the physical, social and psychological effects of HCV treatment? 
5. What are the barriers to prevention and treatment of HCV? 
6. What prevention and treatment resources are available to people who are infected with 
HCV? 
7. What can be done to improve HCV prevention and treatment? 
 
Delimitations 
 
The delimitations of the study were as follows: 
1. Primary data was collected from interviews with experts on HCV. 
2. Summary reports were reviewed by a small sample of individuals who are HCV positive. 
3. Data collected through the interviews was restricted to participants’ professional 
opinions.  
4. Epidemiological data was be gathered and analyzed by the state public health 
epidemiologist. 
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5. Secondary data was collected from various types of documents and archival records 
including: Centers for Disease Control and Prevention, MTDPHHS Epidemiological 
data, National Center for Health Statistics, National Institutes of Health, the World 
Health Organization and refereed journal articles from the University of Montana Library 
Database. 
Limitations 
 
The limitations of this study: 
1. People living with HCV, who reviewed the summary report, may not have been 
representative of all the individuals in Montana living with HCV.  
2. The epidemiological data only reflects those who have been tested for HCV, and whose 
test results have been reported to the state.  Therefore, there may be more individuals 
infected with HCV than are represented by the data. 
3. The vast majority of key informants who were interviewed work in HCV prevention, 
rather than treatment, which could have biased this study. 
4. Key informants who sent out the summary reports did not randomly select people, rather, 
participants were chosen by the key informant based upon likeliness and interest in 
completing the report. 
Definitions of Terms 
 
Acute HCV: There are two ways to define acute HCV. The CDC defines acute HCV as a short-
term illness that occurs within the first 6 months after someone is exposed to HCV (CDC, 
2010a).  In contrast, the Council of State and Territorial Epidemiologists (CSTE) defines the 
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clinical description of acute HCV infection as an acute illness with a discrete onset of any sign or 
symptom consistent with acute viral hepatitis and either a) jaundice, or b) elevated serum alanine 
aminotransferase (ALT) levels > 400 IU/L. Examples of symptoms are: fever, headache, malaise, 
anorexia, nausea, vomiting, diarrhea and abdominal pain. Research has shown that 75-85% of 
acute HCV cases develop into chronic HCV infection (CDC, 2011). For the purposes of this 
research, the first and standard definition of acute hepatitis C will be used when referring to 
acute hepatitis C.  
 
Anti-HCV: Anti-HCV is a term for a person who tests positive for antibodies to HCV. 
According to the Merriam Webster dictionary, an antibody is a protein that is produced after 
stimulation by an antigen (any substance foreign to the body that evokes an immune response) an 
individual becomes infected with HCV, he/she will always have antibodies in his/her blood, 
regardless of whether he/she has cleared the virus or becomes chronically infected (CDC, 
2010a). 
 
Boceprevir (Victrelis) and Telaprevir (Incivek): In May 2011, the U.S. Food and Drug 
Administration approved boceprevir and telaprevir to be used in conjunction with the existing 
HCV treatment drugs: Peg-IFN and RBV. Both boceprevir and telaprevir are in the class of 
drugs called protease inhibitors. Either of these drugs can be used in conjunction with Peg-IFN 
and RBV for a 3-drug combination treatment; however, neither can be used alone and neither can 
be used only with RBV. Both boceprevir and telaprevir must be used with both Peg-IFN and 
RBV. These two new drugs increase the chance of treatment success for those individuals 
infected with HCV genotype 1 (United States Department of Veteran’s Affairs [USDVA], 2011).  
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Chronic HCV: Like acute HCV, there are also two ways to define chronic HCV. The CDC’s 
standard definition of chronic HCV is a long-term illness that occurs when the hepatitis C virus 
remains in a person’s body for six months or more. In comparison, the CDC laboratory criteria 
for chronic HCV is defined by meeting one or more of the following criteria: testing positive for 
anti-HCV by enzyme immunoassay (EIA) verified by at least one additional more specific assay 
or testing positive using a nucleic acid or HCV-RIBA (recombinant immunoblot assay) test 
(CDC, 2012a). For the purposes of this research, the first and standard definition of chronic 
hepatitis C will be used when referring to chronic hepatitis C. 
 
Cirrhosis: The WHO defines cirrhosis as a chronic disease of the liver characterized by nodular 
regeneration of hepatocytes and diffuse fibrosis. Cirrhosis is a more severe, irreversible process 
of liver inflammation, necrosis, and regeneration. With hepatitis C, cirrhosis occurs as a late 
stage of chronic infection, and may take 20-30 years to develop (WHO, 2002).  
 
HCV Carrier: The WHO defines an HCV carrier as a person who has HCV in his or her blood 
even if all symptoms have disappeared. Because the virus is present in the blood, it can be 
transmitted to others (WHO, 2002). 
 
The National Health and Nutrition Examination Survey (NHANES): NHANES obtains 
nationally representative data on the health and nutritional status of the non-institutionalized, 
civilian population of the United States (Denniston et al., 2012). NHANES is comprised of a 
series of surveys. These surveys have been used to collect data on HCV prevalence, which 
allows clinicians to target at-risk groups with educational services and therapeutic options (Chak 
	  
	  
12	  
et al, 2011). The surveys use a complex, stratified, and multistage probability sampling design 
and collects information from approximately 5,000 persons per year using standardized 
household interviews, physical examinations, and testing of biologic sampling (Denniston et al., 
2012). 
 
Pegylated Interferon Alpha (Peg-IFN): Pegylated interferon is interferon that has polyethylene 
glycol (Peg) attached to it. With the added Peg, the interferon has a significantly longer half-life 
and can stay in the body longer and therefore is injected less frequently. This allows for 
subcutaneous injection only once per week, versus the previous three times per week, if used in 
conjunction with daily oral dosage of Ribavirin (Schafer et al., 2007). The duration of Peg-IFN 
and RBV depends on the HCV genotype, viral response, and development of adverse effects. 
Treatment can be either 24 or 48 weeks (Castellvi, 2009).   
 
Ribavirin (RBV): RBV is a drug used to treat HCV. It is taken orally, daily and in conjunction 
with weekly injections of Peg-IFN for 24-48 weeks (Leutscher et al., 2010).  
 
Sustained Virologic Response (SVR): SVR is defined as undetectable HCV-ribonucleic acid 24 
weeks after the end of treatment (Udina, 2009). 
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CHAPTER TWO 
REVIEW OF LITERATURE 
 
HCV is currently the leading cause of liver transplants and hepatocellular carcinoma (liver 
cancer). Hepatocellular carcinoma is the fastest-rising cause of all cancer-related deaths in the 
United States (CDC, 2012b). Moreover, the number of Americans who die from HCV-related 
conditions is increasing, totaling more than 15,000 in 2007 (CDC, 2012b). The majority of 
people in resource rich countries, such as the U.S., become infected with HCV by sharing 
needles or other equipment to inject drugs. Regardless of the number of injection times, if an 
individual injects drugs, he or she is at risk for contracting HCV (CDC, 2010a).  
 
The first section of this review of literature will discuss the behaviors that contribute to HCV 
contraction and the factors inherently influencing those behaviors. The second section will 
address HCV treatment, while the third section will discuss the physical, social and 
psychological effects that result from treatment.  The fourth section will discuss the 
complications that arise from coinfection of HCV with human immunodeficiency virus (HIV).  
Finally, prevention interventions that have been implemented to decrease HCV prevalence will 
be discussed.  
Behaviors Contributing to HCV Infection 
	  
 
In resource rich countries, injection drug use is the single most important risk factor for acquiring 
HCV (Iversen, Wand, Gonnermann & Maher, 2010). The CDC estimates that within five years 
of beginning drug use, between 50-80% of people who inject drugs (PWID) will become 
infected with HCV. Moreover, HCV is generally the first blood-borne virus PWID acquire 
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(CDC, 2002). There are several reasons for the rapid spread of HCV infection amongst PWID.  
The first has to do with viral factors; HCV is transmitted very efficiently through blood 
exposure. Second, HCV can spread quickly due to host factors; a large number of individuals are 
infected and therefore, provide multiple opportunities for transmission to others. The third reason 
for the rapid spread of HCV is due to factors related to PWID. PWID frequently purchase drugs 
and prepare the drug solution together. This solution is then divided among the users (CDC, 
2002). Sharing the drug solution and any other accoutrements used in the drug making process 
such as drug mixing containers, cotton filters, water and syringes, increases the risk of 
transmission if any of the components are infected with HCV (CDC, 2002).   
 
Risky injection behaviors such as needle/syringe sharing and improper sterilization methods lead 
to a greater chance of infection for PWID. This fact partially explains why PWID have 
consistently high prevalence numbers (Korthuis et al, 2012). In a survey of 23 U.S. cities from 
2005-2006, 31.8% of PWID reported sharing needles (CDC, 2009). A recent study done by 
Korthuis et al. found that in a sample of 244 recent PWID, 38.5% of them reported syringe/ 
needles sharing in the past 6 months; less than half of these individuals always used a clean 
needle (Korthuis et al., 2012). Cleaning with bleach was the most common method of 
sterilization among those who cleaned their needles; however, many used less effective cleaning 
methods such as soap and water. Additionally, Korthuis et al. found that more HCV positive 
PWID reported recent syringe/needle sharing compared with those with HCV negative/unknown 
status; however, this was not statistically significant. 
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There are also other circumstances that contribute to the heavy impact of HCV on PWID. The 
first is that people who use injection drugs are at a very high risk of coinfection with HIV and 
HCV (CDC, 2002). This is important because people who are coinfected with HCV and HIV are 
more likely than those with HCV alone to develop end-stage liver disease because HIV 
accelerates the progression of HCV (Swan, 2006). Second, the majority of people who use 
injection drugs also drink alcohol, which not only further damages the liver, but also accelerates 
the advancement of liver disease. Third, research has shown that few PWID are currently 
receiving HCV treatment (Doyle et al., 2012). This can be attributed to the fact that treatment of 
chronic HCV is very expensive, complicated and difficult to follow. Adherence to the treatment 
schedule can be affected by other conditions that PWID may have such as HIV, mental illness 
and alcoholism (CDC, 2002). Moreover, PWID tend to be poor and have unstable living 
conditions, which also create barriers to receiving HCV treatment (CDC, 2002). Finally, the 
stigma surrounding injecting drugs also means that many PWID are marginalized and have little 
or no contact with health care providers (CDC, 2002).  
 
From the review of recent literature, it is evident that sharing injection drug needles/syringes is 
the largest contributing behavior to HCV contraction. People who share needles/syringes 
generally don’t receive treatment because of other confounding factors such as mental illness, 
poverty, alcohol use and expense. This creates a vicious cycle whereby HCV can be spread 
rampantly throughout the PWID population. 
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Factors Influencing Behaviors Leading to HCV Infection 
 
Awareness of HCV infection 
 
Multiple U.S. studies have reported that between 35-65% of current PWID report risky injection 
behaviors such as syringe/needle sharing (Korthuis, 2012). Although prior studies on the effects 
of HCV-infection awareness on risky behaviors demonstrated mixed results, Korthuis et al. 
found that there was an association between HCV awareness, meaning knowledge of HCV-
positive status, and increased needle/syringe sharing. Korthuis et al. believe that this information 
“may reflect a complex cluster of characteristics among HCV-aware PWID in this cross-
sectional study” (pg. 554). The researchers state that the data support that HCV awareness is 
likely a marker for PWID with greater addiction severity, addiction durations (older age among 
HCV-aware) and increased opportunities for HCV testing. For example, HCV aware individuals 
also report an increased use of needle exchange programs (Korthuis et al., 2012).  Korthuis et al. 
believe it may be possible that in populations where higher proportions of PWID are aware they 
are HCV-positive, PWID may embrace a more terminal attitude toward risky injection practices.  
Other studies have similar findings and have stated that HCV is “a risk accepted rather than 
avoided” (Rhodes, Singer, Bourgois, Friedman & Strathdee, 2005). Consistent with this finding, 
a Swedish IDU study found that 74% of those who are HCV-aware shared needles compared 
with 68% of those with unknown status (Norden et al., 2009). 
Demographic Factors 
 
Another factor influencing behaviors that lead to infection with HCV is demographic make-up.  
Korthuis et al. determined that PWID who are more likely to engage in risky injection practices 
are generally young women with lower educational attainment who also use opiates and crack 
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cocaine. Of 244 recent PWID surveyed in the Korthuis et al. study, 92 (37.7%) participants 
reported being positive for HCV, 55 (22.5%) participants were HCV-negative and 97 (39.8%) 
reported unknown HCV status. Compared to those who were HCV negative/unaware, HCV 
positive PWID were more likely to be women (52.2% women, 31.6% men, and 16.2% no 
response, p<.001).   
 
A 2010 Australian study looking at the gender difference in HCV antibody prevalence and risk 
behaviors amongst PWID found that women are at increased risk of exposure to HCV in all 
duration of injection categories except those injecting for 17 or more years (Iversen et al., 2010).  
The duration categories include: four years or less, five to nine years, ten to sixteen years and 
seventeen or more years. The researchers also found that women reported more needle, syringe 
and equipment sharing as compared to men. Moreover, Iversen et al. found that the women in the 
study tended to be younger than the men amongst those injecting for four years or less and those 
injecting for five to nine years. Despite this study’s many strengths, the questionnaire about 
demographics, injecting habits and sexual risk behaviors was self-administered by the Australian 
Needle and Syringe Program Survey (ANSPS).  Since this cross-sectional survey was self-report, 
it is possible subjects gave socially desirable answers (Iversen et al., 2010) 
 
Globally, the incidence of HCV amongst PWID is higher in low- and middle- income countries 
than in high-income countries; therefore, income level is also a factor affecting injection drug 
use (WHO, 2012a).  From this information it is clear that younger women, living in low- or 
middle-income countries, are more likely to inject drugs.  
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HCV Treatment and Costs 
	  
Until recently, there were only two drugs approved for the treatment of HCV, pegylated 
interferon (Peg-IFN) and ribavirin (RBV). In May 2011, however, two new drugs were released: 
boceprevir and telaprevir (United States Department of Veterans Affairs [USDVA], 2011).  
Boceprevir and telaprevir are meant to be taken in combination with Peg-IFN and RBV. The 
purposes of these medications are three-fold: to clear the HCV from the bloodstream, to slow 
down or prevent progression of inflammation and scarring in the liver and to reduce to likelihood 
of developing cirrhosis and liver cancer. Either boceprevir or telaprevir can be used in 
combination with Peg-IFN and RBV for a 3-drug combination treatment. However, neither 
boceprevir nor telaprevir can be used alone and neither can be used only with RBV. The benefits 
of boceprevir and telaprevir are that they increase the likelihood of treatment success for patients 
with genotype 1 HCV, which is the most common genotype in the U.S. In fact, with boceprevir 
and telaprevir added to the Peg-IFN and RBV regimen, up to 75% of patients chronically 
infected with genotype-1 can be cured. Conversely, Peg-IFN and RBV used alone can only cure 
50% of patients with genotype-1 (Doyle, Aspinall, Liew, Thompson, and Hellard, 2012). 
Patients can respond to treatment in one of three ways; first, the patient can have a sustained 
virologic response (SVR). This is a complete response wherein HCV becomes undetectable 
during treatment and remains undetectable 6 months after treatment has been completed and 
stopped. A patient can also have a non-response, which means that the hepatitis C virus did not 
become undetectable as a result of treatment.  Additionally, patients can experience relapse, 
which occurs when the hepatitis C virus does become undetectable but then becomes present in 
the blood again, either during treatment or after treatment is stopped (USDVA, 2011).  
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Using a 3-drug regimen (Peg-IFN and RBV and either boceprevir or tealprevir) significantly 
increases the likelihood of an SVR for genotype 1 patients (USDVA, 2011). The SVR rates of 
boceprevir and telaprevir cannot be directly compared to each other because each has been 
studied only in comparison to Peg-IFN and RBV alone; they have not been compared head-to-
head. In genotype-1 patients being treated in trials, researchers found that in telaprevir trials: 
Peg-IFN and RBV alone witnessed 44% SVR, while the addition of telaprevir increased SVR to 
between 69-75%. In comparison, researchers found that during the boceprevir trials, Peg-IFN 
and RBV alone witnessed only 38% SVR, while the addition of boceprevir increased SVR to 
between 63-66% (USDVA, 2011).  
Costs of Treatment 
 
It is estimated that the cost of a 30-day supply of RBV (based on a dose of 800 mg/day) ranges 
from $500 to $1,100, depending on the manufacturer. This is equivalent to roughly $5,500-
$12,100 per 48 weeks, or approximately 11 months of treatment; this is the recommended 
duration of treatment (USDVA, 2011). Additionally, the cost of four once-weekly injections of 
pegylated interferon also varies by product and ranges from $1,300 to $1,500 per month or 
$14,300-$16,500 per 48 weeks of treatment duration (U.S. Department of Health and Human 
Services, 2006). Therefore, per the recommended treatment duration, an individual seeking Peg-
IFN and RBV treatment could be paying between $19,800-$28,600 out-of-pocket, if this 
individual does not have insurance or qualify for Medicaid. 
Only two U.S. studies have examined the cost-effectiveness of the new treatment, telaprevir 
(CDC, 2012b).  The first study, which defined the birth cohort as persons born during 1945–
1965, estimated a cost per quality-adjusted life year (QALY) gained of $35,700 on the basis of a 
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12-week, response-guided course of telaprevir and Peg-IFN/RBV. The second study defined the 
birth cohort as persons born during 1946–1970 and estimated a cost per QALY gained of 
$39,963 for patients treated with telaprevir in addition to Peg-IFN/RBV (CDC, 2012b). Given 
that PWID, the most susceptible group to contracting HCV, tend to be poor and have unstable 
living conditions, it is likely that most of these individuals do not have insurance or may not 
qualify for Medicaid; therefore, they do not receive treatment because of its expense (CDC, 
2002). For reasons ranging from the nature of HCV progression to the efficacy of available 
treatments, as well as the cost of treatments, most people living with HCV will never undergo 
HCV drug treatment (Swan, 2006). In fact, the U.S. Department of Veterans Affairs identified 
270,000 HCV-infected veterans since implementing HCV screening and testing, yet between 
1996 and 2003, just 8 percent were ever treated (Swan, 2006).  
 
Physical, Social, and Psychological Effects of HCV Diagnosis and Treatment 
 
The interplay of biopsychosocial factors, antiviral treatments and health outcomes is 
exceptionally complex in individuals infected with HCV (Evon, Golin, Fried & Keefe, 2012).  
Individuals infected with HCV experience psychological and somatic problems and report poor 
health-related quality of life (HRQL) (Evon et al., 2012). While diagnosis with HCV can be 
egregious alone, HCV treatment can be even worse due to the exacerbation of many health 
problems. Antiviral treatment of chronic HCV with Pegylated Interferon-Alpha (Peg-IFN) is 
associated with several neuropsychiatric side effects such as fatigue, anhedonia, depression, 
irritability, cognitive disturbances, mania, psychotic symptoms, delirium syndromes, relapse in 
alcohol or drug abuse and even suicidal thoughts (Shaefer et al., 2007). Pre-existing conditions 
such as poor mental health and alcohol or substance abuse can interfere with access to and 
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successful completion of HCV treatment, not to mention the costs of treatment. Moreover, 
perceived stigma is widespread and associated with psychological distress among those infected 
with HCV (Evon et al., 2012). This section of the literature review will encompass the physical, 
social and psychological aspects of HCV diagnosis and treatment.  
 
Effects of HCV Infection 
 
There are many physical side effects of HCV that occur with acute and chronic HCV infection. 
The physical side effects of acute HCV infection include: jaundice, fever, headache, malaise, 
anorexia, nausea, vomiting, diarrhea and abdominal pain (CSTE, 2012). Those diagnosed with 
chronic hepatitis C also experience prominent physical side effects including: fatigue, hepatic 
fibrosis, cirrhosis and hepatoccellular carcinoma (Younossi et al., 2007). Fatigue is among the 
most frequent and disabling features of chronic HCV. The most common side effects of hepatic 
fibrosis, cirrhosis and hepatocelular carcinoma include: weakness, fatigue, loss of appetite, 
nausea, vomiting, weight loss, abdominal pain, itching and spiderlike blood vessels on the skin 
(National Digestive Diseases Information Clearinghouse [NDDIC], 2012). 
 
Societal stigma has been defined as a “mark” that is deeply discrediting and ruins the “marked 
person’s normal identity” (Goffman, 1963). Infectious diseases carry enormous societal stigma; 
therefore, by association, a person infected with HCV has the potential to be highly stigmatized 
(Evon et al., 2012). Applying the HIV Stigma Framework Model to HCV diagnosis can help to 
understand how individuals experience stigma and the mechanisms by which societal stigma 
affect HCV outcomes (Evon et al., 2012). This model suggests that societal stigma evokes 
stigma mechanisms, which can create harmful outcomes. Evon et al. define stigma mechanisms 
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as ways that individuals react psychologically to knowledge that they possess the “mark” and 
include: enacted stigma (experience of prejudice and discriminations), anticipated stigma 
(expectations of future prejudice and discriminations), and internalized stigma (endorsement of 
negative beliefs and feelings about themselves). Therefore, these stigma mechanisms may 
negatively affect psychological, behavioral and social outcomes.  
 
A review of 21 studies on HCV-related stigma suggests that 22%-100% of study participants 
perceived stigma related to HCV infection (Evon et al., 2012). Additionally, evidence from HCV 
stigma studies is consistent with the HIV Stigma Framework. For example, anticipated HCV 
stigma leads to frequent worry about HCV “being discovered.” In fact, up to 25% of patients 
report nondisclosure of HCV to friends and 55% report nondisclosure to physicians. Moreover, 
66% of patients report internalized stigma, such as shame and 63% report insecurity. Stigma is 
also highly associated with poor psychological well-being, such as depression (Evon et al., 
2012). 
 
There are also many psychological side effects associated with HCV infection. Patients with 
HCV who are not on treatment report many emotional disturbances, including depressive 
symptoms (70%) and irritability (74%) (Evon et al., 2012). In fact, it is reported that one quarter 
of HCV patients meet diagnostic criteria for current major depression, 36% meet criteria for 
lifetime depression and up to 70% report some level of depression. To make matters worse, HCV 
treatment can have adverse side effects on patients, such as treatment induced-depression 
(Sockalingam, Links & Abbey, 2011).   
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Effects of HCV Treatment 
 
Each treatment type (Peg-IFN, RBV, boceprevir and telaprevir) has many side effects. Peg-IFN 
causes the most side effects of all medications and since this is one of the required treatments (in 
addition to RBV) all patients will experience some of the symptoms. The side effects of Peg-IFN 
include: fatigue, flu-like symptoms, mood changes, drop in platelet, white blood cell and 
neutrophil count; loss of appetite, nausea or change in bowel habits, weight gain or loss, hair 
loss, changes in thyroid function, increase in blood sugar level and insomnia. The side effects of 
RBV (another required treatment) are: anemia, sore throat, cough, shortness of breath, rash and 
harm to embryo or fetus of pregnant patients. The side effects of boceprevir are: impaired sense 
of taste and anemia. Finally, the side effects of telaprevir are: anemia, rash, itching and nausea 
(USDVA, 2011).  
 
Depression is the most common psychological side effect of Peg-IFN/RBV HCV treatment 
(Sockalingam et al., 2011). In fact, approximately 20-30% of patients receiving Peg-IFN therapy 
experience depression side effects (Morasco et al., 2007). Since Peg-IFN and RBV are included 
in all HCV treatments, all individuals receiving HCV treatment are at risk of depression. Studies 
suggest that patients undergoing Peg-IFN therapy are at the greatest risk of developing 
depression during the first 12 weeks of therapy with Peg-IFN and RBV. However, all side effects 
tied to Peg-IFN/RBV treatment are usually reversible within a few days of cessation of therapy 
(Scalori et al., 2005).  
 
Depression associated with antiviral treatment is generally called interferon-induced depression 
(Udina et al., 2012). Early detection and treatment of depressive symptoms are paramount as 
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depressive patients usually experience poor quality of life, suicide ideation and lack of treatment 
adherence. In a systematic literature review and meta-analysis, Udine et al. report a cumulative 
incidence of major depressive episode (MDE) during interferon treatment at 25% at 24 weeks 
after initiation and 28% after 48 weeks of treatment. The researchers determined that none of 
these patients were depressed before starting treatment, as confirmed by the Diagnostic and 
Statistical Manual of Mental Disorders (DSM)/International Statistical Classification of Diseases 
and Related Health Problems (ICD). The results from this research indicate that 1 out of 4 
patients starting combined treatment with Peg-IFN and RBV may develop a full MDE.  
Although treatment can cause interferon-induced depression, Ghany et al. (2009) state: 
“treatment can be safely administered provided there is a comprehensive pretreatment 
psychiatric assessment, a risk benefit analysis and provisions for ongoing follow-up of 
neuropsychiatric symptoms during antiviral therapy by a multidisciplinary team” (Ghany, 
Strader, Thomas & Seeff, 2009, p. 1362). Therefore, it is imperative that clinicians assess 
patients’ risk of developing interferon-induced depression before starting treatment (Udina et al., 
2012). 
HCV Coinfection with HIV 
 
In the United States, HCV prevalence among all People Living With HIV/AIDS (PLWHA) is 
estimated to be 15 to 30 percent; however, it is more than three times higher—between 50 to 90 
percent—among people who acquired HIV through injection drug use (Swan, 2006). 
Furthermore, HCV is approximately ten times more infectious than HIV (Sulkowski, Moore, 
Mehta, Chaisson & Thomas, 2002).  Globally, 20% of those infected with HIV are also 
chronically infected with HCV, with the majority living in low- and middle-income countries 
(WHO, 2012a).   
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People who are coinfected with HCV and HIV are more likely than those with HCV alone to 
develop end-stage liver disease because HIV accelerates progression of HCV (Swan, 2006).  
Therefore, progression to cirrhosis occurs faster in individuals with HCV and HIV coinfection 
(Barriero, Vispo, Labarga & Soriano, 2012). In fact, a meta-analysis of eight studies reported 
that coinfected patients were twice as likely to develop cirrhosis than patients with HCV alone.  
Coinfected patients also had a six-fold greater risk for hepatic decompensation, which is defined 
as decreased liver function due to damage for which the liver cannot compensate (Swan, 2006).  
 
Treatment Complications of Coinfection 
 
Response to Peg-IFN/RBV therapy is lower in patients with chronic HCV coinfected with HIV, 
as compared with HCV monoinfected individuals (Barriero et al., 2012). This is due to several 
reasons: the first being that, compared with patients infected with only HCV, coinfected patients 
have a lower virologic response. Additionally, those who are coinfected frequently have 
comorbid conditions, such as substance abuse; this is a contraindication to treatment for many 
patients. To make matters worse, antiretroviral drugs, taken by coinfected patients, may interact 
with other medications, increasing the risk of complications and the complexity of treatment 
regimens (Naggie & Sulkowski, 2012). Therefore, a large proportion of HIV/HCV coinfected 
patients are not treated due to contraindications, do not complete therapy due to serious adverse 
events, or simply do not wish to receive a treatment with such adverse side effects, such as 
depression (Naggie & Sulkowski, 2012).  
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Prevention Interventions 
 
Because there is currently no vaccine available for HCV, efforts to prevent transmission amongst 
PWID need to focus on minimizing injection drug use or reducing needle/syringe sharing and 
contamination of injecting equipment (Sacks-Davis, Horyniaj, Grebely & Hellard, 2012). Sacks-
Davis et al. suggest that a multifaceted approach must be taken in order to prevent HCV 
transmission amongst PWID. This means that interventions need to incorporate a combination of 
strategies that target the individual drug user (including counseling and peer-education) as well 
as strategies that aim to bring about structural change for example, needle/syringe exchange 
programs. Although there is substantial global burden of HCV amongst PWID, there is very little 
research available on HCV prevention, as compared with HIV prevention (Sacks-Davis et al., 
2012).    
 
Syringe exchange programs (SEPs) are known to reduce transmission of not only HCV, but also 
HIV and hepatitis B virus (HBV) (CDC, 2010b). For this CDC report, the term “syringe” refers 
to both syringes and needles. In order to reduce transmission of HCV, it is of paramount 
importance that PWID use a new, sterile needle and syringe for each injection. Therefore, SEPs 
reduce transmission of HCV, among other bloodborne pathogens, by providing free sterile 
syringes and collect used syringes from PWID. As of March 2009, the most recent year of data 
collected, a total of 184 SEPs were known to be operating in 36 states, the District of Columbia 
(DC), and Puerto Rico. Of these, 123 (67%) SEP directors participated in a mail/telephone 
survey conducted by the North American Syringe Exchange Network (NASEN) and Beth Israel 
Medical Center (New York, New York) that covered program operations for 2008. This 
Morbidity and Mortality Weekly Report (MMWR) report summarizes the findings from that 
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survey. The results indicate that the majority of the SEPs reported offering preventive health and 
clinical services in addition to basic syringe exchange. Moreover, 65% of SEPs offered hepatitis 
C counseling and testing. By providing comprehensive prevention services and referrals to 
PWID, SEPs can help reduce the spread of bloodborne infections and increase access to health 
care and substance abuse treatment. Thus, SEPs serve as a primary source of health services for 
PWID (CDC, 2010b).  
 
Although SEPs seem to be common across the U.S., NASEN reports that only one SEP exists in 
Montana; it is located at the Western Montana Gay & Lesbian Community Center in Missoula 
(NASEN, 2012). However, according to NASEN, this is the only SEP that has given consent to 
make their contact information public; therefore, it is possible that other SEPs exist but have 
chosen to not make their contact information public. Montana needs more SEPs to be developed 
to reduce HCV, HIV and HBV infections within the state.   
Conclusion 
 
In summary, hepatitis C is a complex virus with even more intricate treatment regimens and side 
effects due to treatment. Although treatment of HCV infection is advisable in order to minimize 
transmission and decrease overall prevalence of the virus, it is not currently feasible for most 
people because of the substantial treatment costs.   
 
It is evident from the literature that PWID are at the greatest risk of contracting HCV. PWID 
may embrace a more terminal attitude toward risky injection practices and therefore be more 
susceptible to contracting/spreading HCV. Those who are most likely to inject drugs include 
younger women in low- or middle-income countries.   
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Simply being diagnosed with HCV can be difficult in itself, but to make matters worse, HCV 
treatments, if undertaken, can affect an individual’s physical, social and psychological well-
being. Moreover, people who acquired HIV through injection drug use are very likely to also be 
coinfected with HCV. Treatment can be very complex for individuals who are coinfected with 
HCV and HIV; these individuals often go untreated. From this review of recent literature, it is 
evident we need more prevention programs and interventions to minimize transmission and 
thereby decrease the incidence and prevalence of HCV. 
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CHAPTER THREE 
METHODOLOGY 
	  
Purpose Statement 
 
This study aimed to fill gaps in information about HCV in Montana by providing data regarding 
HCV transmission, factors influencing transmission, epidemiological information, the physical, 
social and psychological effects of HCV diagnosis and treatment, information about barriers to 
prevention and treatment, current available resources to those presently infected with HCV and 
what can be done to improve HCV prevention and treatment in Montana. The Montana 
Department of Public Health and Human Services (MTDPHHS) and local health departments 
will use information from this study to help increase awareness of how HCV impacts Montana 
residents. Information from this study could lead to better and more optimally targeted 
prevention efforts.  
Description of Target Population 
 
Individuals who are living in Montana and infected with HCV were the focus of this study.  
Information about Montanans living with HCV was gathered by several means. Specifically, data 
was gathered via a review of current literature; interviews with health care professionals whose 
work includes HCV prevention and treatment; written responses to questions posed to 
individuals over the age of 18 who are infected with HCV; and epidemiologic data provided by 
the Montana Department of Public Health and Human Services.    
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Protection of Human Subjects 
 
The human subjects application material and consent forms were completed in accordance with 
the University of Montana Institutional Review Board (IRB).  
 
Research Design 
 
This study utilized a descriptive case study design. A case study design is ideal when looking at 
research that examines present-day issues surrounding behavior that cannot be manipulated or 
examined in a controlled setting. Yin (2003) states that when investigating a phenomenon, such 
as HCV infection in Montana, “the case study method allows investigators to retain the holistic 
and meaningful characteristics of real-life events” (Yin, 2003, p. 1).  Figure 1 below illustrates 
data triangulation using various collection methods under the case study design for this research: 
Figure 1. Case Study Design 
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Procedures 
 
Both primary and secondary data sources were used in this study. The primary data sources were 
key informant interviews with health care professionals and summary report by Montanans 
currently living with HCV. Because there are no studies specific to Montana, national studies 
were used to fill in the gaps.  Previous research studies and state epidemiological data regarding 
HCV comprised the secondary data sources. 
 
Table 1 Research Questions and Data Collection Methods 
Research Questions: Data Collection Methods: 
1. What is the epidemiology of HCV in 
Montana? 
a. What is the incidence and prevalence 
of HCV in Montana? 
b. What are the demographic 
characteristics of those infected with 
HCV and living in Montana? 
Secondary Data: These data were provided by 
the MTDPHHS epidemiologist. 
2. What are the behaviors that contribute to 
infection and the factors that influence those 
behaviors in Montana? 
Primary Data: This information came from 
key informant interviews with health 
professionals and from individuals in 
Montana who are living with HCV. 
3. What are the physical, social and 
psychological effects of HCV in Montana? 
Primary Data: This information came from 
key informant interviews with health 
professionals and from individuals in 
Montana who are living with HCV. 
4. What are the physical, social and 
psychological effects of HCV treatment in 
Montana? 
Primary Data: This information came from 
key informant interviews with health 
professionals and from individuals in 
Montana who are living with HCV. 
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5. What are the barriers to prevention and 
treatment of HCV in Montana? 
Primary Data: This information came from 
key informant interviews with health 
professionals and from individuals in 
Montana who are living with HCV. 
6. What prevention and treatment services are 
available in Montana to people who are 
infected with HCV? 
Primary Data: This information came from 
key informant interviews with health 
professionals and from individuals in 
Montana who are living with HCV. 
7. What can be done to improve HCV 
prevention and treatment in Montana? 
Primary and Secondary Data: This 
information came from the literature, key 
informant interviews with health professionals 
and from individuals in Montana who are 
living with HCV. 
 
Instrumentation, Sample Selection, Data Collection, and Data Analysis 
 
Primary Data Sources 
Key Informant Interviews 
 
Sample Selection 
 
An initial convenience sample of four health professionals, who were known to the researchers, 
was recruited to participate in face-to-face or telephone interviews regarding HCV infection.  
Snowball sampling was used to schedule more interviews with other health professionals. 
Specifically, after an interview with a key informant, he or she was asked to recommend other 
health professionals with HCV expertise who may be willing to volunteer for an interview. The 
researcher then contacted potential interviewees, explained the study to them, and asked them if 
they were interested in participating in an interview. Interviews continued until data saturation 
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was achieved; in the case of this research, data saturation was reached at eight interviews with 
ten key informants. Two of the interviews involved two key informants. 
Instrumentation 
 
Interview questions for this study were developed based upon stages two through five of the 
PRECEDE logic model and reflected the research questions. The interview schedule (see 
appendix A) included questions that were directed at the following topics: behaviors and 
influencing factors contributing to HCV infection in Montana; the barriers to preventing and 
treating HCV infection in Montana; the physical, social and psychological effects of HCV and 
HCV treatment in Montana; the availability of prevention and treatment services in Montana for 
those infected with HCV; actions that can be taken to improve HCV prevention and treatment in 
Montana and any other thoughts related to individuals living with HCV in Montana. This 
interview schedule provided a basic structure for the presentation of the aforementioned topics; 
however, when other relevant issues arose during the interview, they were also discussed. The 
questions were evaluated and revised by the expert review panel prior to finalizing the interview 
schedule.   
 
Data Collection 
 
A private, convenient meeting time and place was arranged with key informants who were 
willing to volunteer for the study via face-to-face or telephone interviews. Prior to beginning the 
interview, the key informant was given a verbal description of the study and was asked to read 
and provide verbal consent (see Appendix C). Interviews were audio recorded and lasted roughly 
30-45 minutes. Immediately upon transcription of the interview, the files were destroyed. Names 
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of interviewees were not connected to the data. Following the interview, the key informant was 
asked to recommend other health professionals who have experience working with people living 
with HCV and who may be interested in volunteering for an interview. Potential key informants 
were contacted by the researcher who explained the study and inquired about their interest in 
participating in an interview. A convenient time and place for the interview was arranged with 
the individuals who agreed to be interviewed. 
 
Following each interview, contact summary sheets were completed to record general information 
about the key informant including location of the interview, place of employment, professional 
position, date and length of interview and the interviewer’s general impressions of the interview 
process (see Appendix D).   
 
Data Analysis 
 
Primary data was analyzed qualitatively using Ulin et al.’s five-step qualitative data analysis 
process (Ulin, Robinson, & Tolley, 2005). Immediately after each key informant interview took 
place, the researcher reviewed all notes and audio recordings. Each key informant interview was 
transcribed in its entirety; after transcription, all audio files were destroyed.  
 
There are five steps in Ulin et al.’s qualitative data analysis process. The first step of Ulin et al.’s 
qualitative data analysis process was reading, which is described as: “developing an intimate 
relationship with data” (Ulin et al., 2005, p. 145). This was a process that fully engaged the 
researcher in the data. This made the researcher more familiar with the transcripts’ content. This 
process took place after each interview was conducted and transcribed. Becoming familiar with 
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the data as it was collected allowed the researcher to identify gaps in the questions or other areas 
of the interview process that needed improvement.  
 
The second step in the process described by Ulin et al. (2005) was coding, which is described as: 
“identifying the emerging themes” (Ulin et al., 2005, p. 146). Upon completion of the 
transcriptions, the researcher read through the interview and identified emerging themes. These 
potential themes were added to a list, which was then further narrowed in order to minimize the 
number of themes. The research assistant then printed transcriptions in order to identify parts of 
data that were related to specific themes. 
 
The third step in the data analysis process as defined by Ulin et al. (2005) was “displaying data” 
as “distinguishing nuances of a topic” (Ulin et al., 2005, p. 157).  This was essentially: “laying 
out or taking an inventory of what you know related to a theme; capturing the variation or 
richness, of each theme; separating qualitative and quantitative aspects; and noting differences 
between individuals or among subgroups” (Ulin et al., 2005, p. 157).  During this step, the 
research assistant further investigated the themes and data in order to identify themes that may 
have been present but could have been disregarded.   
 
Data reduction was the fourth step and was described as “getting the big picture” (Ulin et al., 
2005, p. 160), or “the process of distilling the information to make visible the most essential 
concepts and relationships” (Ulin et al., 2005, p. 160). This step took place once all data was 
collected and the researcher became very familiar with the data in addition to recurrent themes. 
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The researcher also reviewed themes for internal validity. This was completed in order to 
condense the themes.   
 
The last step in Ulin’s five-step qualitative data analysis process was interpretation. Ulin et al. 
(2005) described this as “the act of identifying and explaining the data’s core meaning…It is to 
identify ways that the many different pieces of the research puzzle (emerging themes, 
connections and contradictions) fit and what it all means” (Ulin et al., 2005, p. 162).  
 
Investigator triangulation was used in order to develop a comprehensive understanding of the 
key informant interviews from different perspectives and to reduce individual researcher bias. 
The two individuals who were participated in the investigator triangulation took a Human 
Subjects Protection Course and were approved as part of the research team by the Institutional 
Review Board (IRB). One individual is a graduate student research assistant while the other is a 
community based research assistant.  
 
All researchers reviewed the transcripts, presented their breakdown of emergent themes and then 
discussed their findings with one another in order to find common ground. This resulted in the 
final theme breakdown of the key informant interviews, as presented in Chapter 4. Once this 
process was complete, secondary data was used to fill in gaps in information and to support, and 
further explain results.  
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HCV Positive Summary Reports 
 
Sample Selection 
 
Upon completing their interviews, three key informants, located in Montana Health Planning 
Regions three, four and five (see Appendix G), were asked to mail or hand out summary reports 
to 12-20 of their clients/patients who are HCV positive. All HCV positive clients/patients were 
asked if they would like to participate in the study. Only those who were interested read, 
completed and mailed back the anonymous summary report to the researchers.  
Instrumentation 
 
Information from the literature review, key informant interviews and epidemiologic report was 
compiled, synthesized and formatted into a report that highlighted the major findings. The 
summary report included five Montana specific summary sections in addition to epidemiological 
information about HCV in Montana:   
1. Transmission of HCV 
2. Environmental Factors that Contribute to Infection with HCV 
3. Effects of Living with HCV and Effects of HCV Treatment 
4. Barriers to HCV Prevention and Treatment 
5. Ways to Improve HCV Prevention and Treatment 
 
Each section of the report was concluded with a space for participants to record their responses 
to the following two questions:   
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1.  Are there statements in the section above that you believe are inaccurate or with which you 
disagree?                                                                                                                                                     
2.  Is there any other information about this topic that you would like to add? 
 
Data Collection 
 
Key informants who agreed to hand/mail out summary reports were sent 12- 20, depending on 
how many they requested. An informed consent form (see Appendix E), epidemiological data 
collected and analyzed by the state epidemiologist, and a $30 cash incentive for completing the 
summary report were affixed to the front cover of each summary report. Within the summary 
report, there were also instructions for completing the report (see Appendix F) and an optional 
demographic form (see Appendix G). Equal numbers of self-addressed and stamped return 
envelopes were included in the package sent to key informants.  
Data Analysis 
 
Comments from participants were reviewed using Ulin et. al.’s (2005) five-step qualitative data 
analysis process, as described in the previous data analysis section. The final theme breakdown, 
as presented in Chapter 4, was a result of investigator triangulation among the research team. 
Areas of agreement and disagreement with the summary report were noted and integrated into 
the final report.  
 
Demographic data was analyzed using the Statistical Package for the Social Sciences 21 (SPSS). 
Frequencies were run on the data to determine the number of respondents in each category (ie. 
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gender, age, income and region of the state). and the percentage of respondents representing each 
category.  
Secondary Data Sources 
 
Literature Review 
 
Given the lack of information about HCV in rural areas, and specifically in Montana, the 
scientific literature was used in conjunction with primary data collected by the researcher to 
enhance understanding and fill in gaps related to: behaviors that contribute to HCV contraction 
and the factors influencing those behaviors; HCV treatment and costs; the physical, social and 
psychological effects of HCV and HCV treatment; complications arising from coinfection with 
HCV and HIV and finally, prevention interventions that have been previously implemented to 
decrease HCV prevalence. Information was collected from various types of documents and 
archival records including: Centers for Disease Control and Prevention, National Center for 
Health Statistics, National Institutes of Health, the World Health Organization as well as refereed 
journal articles from the University of Montana Library Database. 
 
Epidemiological Data 
 
State epidemiological data specific to people living with HCV in Montana was examined by the 
researchers. Historically, data regarding HCV infection has been collected by the state public 
health department, but was not systematically entered into a database and analyzed. The 
researchers worked with the state epidemiologist to determine the limitations of the current HCV 
data and to develop a preliminary picture of the segments of the population (e.g., age, sex, race) 
that are infected with HCV. Furthermore, the epidemiological data provided information about 
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changes and/or variations in the prevalence over time and in different Montana counties. This 
information helped establish the rates and distribution of HCV in Montana.  
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CHAPTER FOUR 
 
RESULTS 
 
 
The purpose of this study was to fill gaps in information about HCV in Montana by providing 
Montana specific information about HCV transmission; factors influencing transmission; 
physical, social and psychological effects of HCV diagnosis and treatment; barriers to prevention 
and treatment; current available resources to those presently infected with HCV; ways to 
improve prevention and treatment and epidemiological data about HCV in Montana. This study 
used both primary and secondary sources. The results are presented below, beginning with the 
primary data, the key informant interviews and summary reports, and ending with the secondary 
data, the epidemiology of HCV in Montana. 
 
Primary Data 
 
Key Informant Interviews 
 
From December 2012 to February 2013, eight interview sessions with ten key informants helped 
to fill gaps in information about HCV in Montana. Seven females and three males were involved 
in the interviews. Additional demographics are listed below:  
• 2 – public health nurses  
• 1 – nurse practitioner who treats HCV positive patients 
• 2 – state employees who perform HCV prevention work 
• 3 – outreach workers in the HIV/HCV community 
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Key informants came from the following counties: Yellowstone (4 interviews), Lewis and Clark 
(1 interview), Gallatin (1 interview), Flathead (1 interview), and Missoula (1 interview).  
 
The key informant interviews ranged in duration from twenty to forty five minutes.  Five of the 
interviews were completed face-to-face, while three of the interviews were administered over the 
phone. All interviews were conducted and transcribed by the research assistant. Upon completion 
of transcription of all interviews the data was analyzed qualitatively. This was completed by a 
formal process as outlined by Ulin et al (2005). The research assistant became familiar with 
interview transcriptions, identified emerging themes, explored and condensed themes, identified 
patterns and drew connections, and arranged the themes into sections. Investigator triangulation 
with the research team also was used to determine common themes and avoid individual 
researcher bias. Finding the common ground among themes identified by the research team 
resulted in the final delineation of themes from the key informant interviews.  
 
After the interviews were transcribed and analyzed, themes were organized into seven sections: 
1) HCV Transmission and Risk Factors; 2) Environmental Factors Influencing HCV Infection 
and Transmission; 3) Negative Effects of HCV; 4) Barriers to HCV Treatment; 5) Barriers to 
HCV Prevention; 6) Ways to Improve HCV Prevention; and 7) Ways to improve HCV 
Treatment. The number of themes per section varied from two themes to seven themes. Included 
with each theme are supporting quotations from the key informant interviews. In order to 
enhance reading ease, extraneous words such as “like,” “you know,” “yeah,” etc. and other 
words that affected the quotation were removed.  
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Section 1: HCV Transmission and Risk Factors 
Theme 1: HCV Transmission through Injection Drug Use 
 
The majority of key informants stated that currently, the most common transmission route of 
HCV is through the sharing of infected needles and “works” to inject drugs. As confirmed by 
key informants, the works are defined as equipment used to inject drugs (ie. the cooker, cotton 
filter, water, drug mixing containers and tourniquet). Furthermore, key informants indicated that 
individuals who use injection drugs often either inject together or let someone else prepare the 
solution for them. This can lead to a greater risk of HCV contraction if the person creating the 
solution or injecting the drugs for another person is HCV positive.  
 “In [Montana County], there’s a lot of drug use…meth, oxycotins and most of them 
 shoot, so [there’s] heavy drug use [and] we’re seeing HCV through that.” 
 – Key Informant (KI) #2 
 
 “As far as behaviors [contributing to infection with HCV,] of course, injectable drug use 
 is number one.” – KI #3 
  
 “Injection drug use isn’t the only way you can get HCV, but it’s one of the main ways.” 
  – KI #6 
 
 “I see a lot of couples who do it together and say, “Well he fixed it for me and got it 
 ready for me.” And I say, “Okay, is he positive for HCV? And who else did he get it 
 ready for?...it’s that intimate thing of somebody else shooting you up.” – KI #5 
 
 “I don’t think a lot of drug users know that if you’re sharing the works (the spoon, cotton 
 needles, water, etc.)…you can also spread [HCV] that easily. I don’t think they’re 
 aware of that.” – KI #7 
 
  
Theme 2: Risk Factors that Lead to Infection with HCV 
 
The majority of key informants mentioned that there are high and low risk routes of 
transmission. The highest risk of transmission occurs when sharing infected syringes/needles or 
works. Key informants mentioned that low risk routes of transmission would include tattooing 
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and sharing of personal items. Although they are unlikely ways to contract HCV, it is still 
possible. 
 “I believe it’s intravenous drug use (IDU) and I think tattooing in the earlier days had a 
 big effect on [the transmission of HCV]. In the earlier days I worked a lot with the tattoo 
 artists…before they were regulated. Just their practices, I think probably spread a lot of 
 HCV…They’re supposed to use individual ink wells and then also I think a lot of people 
 were a little more apt to do at-home tattoos and then of course, in prison they do a lot of 
 self-tattooing, so I believe that also contributes. A lot of people who have ink have HCV.” 
  – KI #7 
 
 “I’ve had two young ladies in the last two years that came in a got tested. The only 
 reason they got tested was because they were living in the dorm at [Montana University] 
 and the roommate had Hep C and they were sharing her razor to shave their legs. And 
 she came out positive. That’s really low risk, but if you’re doing it everyday, and there’s 
 blood, then that’s a risk factor.” – KI #2 
 
 “Well, the main risk factor [for HCV] that we’ve been seeing and treating over the past 
 few years of course, has been, IV drug use and intranasal drug use…Undiagnosed or 
 untreated mental illness [can] lead to high-risk behaviors [such as] needle sharing and 
 that kind of thing.” – KI #8 
 
Section 2: Environmental Factors Influencing HCV Infection and Transmission 
Theme 1: Poverty 
 
The concept that poverty is a factor that affects the transmission of HCV was confirmed by many 
of the key informants in this study. In fact, most key informants believed that poverty was a main 
contributor to the spread of HCV. This is explained by the fact that in general, poverty and 
addiction tend to exist simultaneously and PWID tend have issues with addiction.  
 “Definitely socioeconomic background [contributes to infection with HCV] . Drugs and 
 alcohol are a big factor. Most of the people we deal with are low income families, in and 
 out of jail.”– KI #2 
 
 “I do think it’s socieoeconomic and poverty [relating to HCV transmission]…think of 
 pockets in the state like [Montana City] that have tremendous drug use problems. That 
 too is related to poverty. Life is so crappy that you have to use drugs to maintain.” 
  – KI #3 
 
	  
	  
45	  
 “I think we see a lot of addictions with clients in poverty. Up here we’re got a lot of 
 people where there are just small sub-cultures almost. Our county covers a big distance. 
 There’s a lot of…I mean, I think about…towards [Montana City] there’s a lot of issues 
 up there. It’s a lot of poverty. I’m not trying to be judgmental; it’s just what we see… 
 poverty and these issues go hand in hand.”– KI #5 
 
 
Theme 2: Lack of Education 
 
Lack of education about HCV and therefore unawareness of the ways it is transmitted was also 
found to be an environmental contributor to infection with HCV. Most key informants mentioned 
that the public is not knowledgeable because there is a lack of education in the schools about 
HCV and how it is transmitted. While HIV prevention has for many years been taught in 
Montana, students are not taught about how to prevent infection with HCV. Most key informants 
stated that HCV education needs to start in middle school because that is the age that many kids 
start to experiment with drugs and other risky behaviors. 
 “Junior high kids, they say 6th, 7th and 8th graders, are where you should do that kind of 
 education [about HCV] because that’s where they are really forming their lifestyle 
 habits…that’s when they determine their lifestyle habits as far as lifestyle, nutrition, diet, 
 exercise, drug use…those are their most formative years.”  – KI #7 
 
 “I think, there’s not a lot of education around about it. I think people don’t get educated 
 about HCV until after they’ve likely been infected. Oftentimes, they don’t care at that 
 point.” – KI #6 
  
 “There’s a lot of people that don’t even know that they have [HCV] and don’t know 
 anything about it. They’re doing all these risky behaviors, injecting drugs or whatever 
 and they don’t know they have it. I’d say education is a big piece. I wish that we could 
 start in middle school or at least high school and give that information when kids start 
 using drugs in high school…It would be great if we could start earlier with educating 
 people.” – KI #4 
 
 “We need to get started talking to their family, their kids. I go to the schools and I talk 
 about HIV and gonorrhea and stuff and I talk about HCV too. They at least need to know 
 that it’s transmitted blood-to-blood.” – KI #2 
 
 “[Middle School is] where we need to offer the education though because that’s where 
 the behaviors start!” – KI #5 
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Theme 3: Access to Clean Needles/Syringes 
 
A lack of access to clean syringes/needles also is a major contributor to infection with HCV.  
The majority of key informants stated that the lack of access to clean needles in Montana is one 
of the largest contributors to HCV infection, due to the high rate of HCV among PWID. Without 
clean needles to use for injection drug use, HCV transmission is much higher.  
 “I think it’s not having access to clean syringes [in reference to the question about the 
 behaviors leading to infection with HCV in Montana]…Yeah, it would be the lack of 
 clean needles, they’re hard to get. ” – KI #4 
 
 “Definitely lack of access to syringes. People [don’t] feel like they have options. I think 
 sometimes a lot of the communities here are very share-y. That’s how [they] show each 
 other that [they] care. [They] just don’t realize that [they] could be sharing other things 
 too.” – KI #6 
 
 “Our laws about needle exchange are problematic. Our culture of providing that 
 education…if we tell them how to inject safely, [people think] we’re promoting it.” 
 – KI #5 
 
 “We need policy for new…doesn’t have to be an exchange…a drop/relax in laws for 
 people of all needle drives. Take away the misdemeanors for felonies.” – KI #1 
 
 “Probably the in-availability of clean needles [in reference to environmental factors 
 influencing HCV infection]. Sharing needles, people sharing needles…It’s hard to get 
 clean needles. – KI #7 
 
   
Theme 4: Prison and Jail 
 
Most key informants mentioned that HCV is very common in the Montana prison system. This is 
for a variety of reasons, but the main reason is that those who are incarcerated tend to share 
needles to not only inject drugs, but also to create homemade tattoos. Those who are incarcerated 
tend to share needles because needles are prohibited in prison. This can be problematic because 
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many individuals who become infected leave jail or prison and continue those practices in their 
home communities. This cycle leads to greater overall HCV infection rates.  
 “I think that HCV will be the next disease that CDC will take on. Just because when we 
 go into the jail and test people, we have anywhere from a 35%-45% positivity rate. That 
 is high. It’s lifestyle choices…it’s IV drug use and tattooing.” – KI #7 
 
 “We go to [Montana Half-Way House] and probably about 60% of the people are HCV 
 positive. So it’s a high rate in the jails and half way houses and such.” – KI  #2 
 
 “I see a number of people who have done time or are in the system for one reason or 
 another and they have been in prison and they’ve been out…our economy sucks just like 
 everywhere else. There’s no way around it. They don’t have jobs, they just…they go 
 back to hanging out with the people they were previously hanging out with…” – KI  #5 
 
Section 3: Negative Effects of HCV 
Theme 1: Physical Effects of Living with HCV 
 
Most key informants agreed that having HCV causes disabling fatigue; people just don’t feel 
good when they are infected with HCV.  
 “[HCV] wears you down every day…emotional, mental, it takes a toll everyday…the 
 physical part, it’s draining.” – KI  #4 
 
 “The most common complaint is fatigue. And there’s a real stigma attached. People feel 
 isolated. It’s not like people can talk to their coffee club about this diagnosis.”– KI  #8 
 
 “Obviously, physically, they feel crummy. They’re tired; they have all the side effects, 
 health effects, nutrition effects.” – KI  #5 
 
 “Sometimes [people living with HCV will] have more joint pain than patients who don’t 
 have HCV. That can be a physical result of the viral load. And, occasionally they get a 
 pretty good rash. That can be related to effects of Vitamin C, a sun-related rash that can 
 be pretty debilitating…Then it depends on if they’ve developed advanced liver disease 
 and if they develop the side effects of liver disease.”– KI  #8 
 
 “I think it’s hard for some families because I’ve heard them say, “Well, it seems like he’s 
 lazy, he’s not doing what he should be doing, helping around the house.” Because they 
 look like nothing’s wrong, but they’re sick. It’s hard for some family members to get 
 that, you know?” – KI  #4 
 
  
	  
	  
48	  
Theme 2: Social Effects of Living with HCV and being treated for HCV 
 
The social effects of living with HCV and receiving HCV treatment are similar because the virus 
itself carries extreme stigma. The majority of key informants agreed that the overwhelming 
social effect of both HCV diagnosis and treatment is stigma.  
“If you have HCV, you’re one of those people…Even in the  drug world there’s stigma 
with it. It’s weird because you know…it all comes down to well, if you knew you had 
HCV and you’re sharing your needles…it’s like, “Really you guys? You’re all dong the 
same thing.” But, still stigma involved.”– KI #2 
 
 “There’s a lot of stigma, there’s a lot of hesitation to talk about it, hesitation to screen 
 for it in the clinic, “well, I’m sure she doesn’t have that..”, well, let me tell you, if you 
 looked at my waiting room, you would not be able to pick out those patients. Some, yes.” 
 – KI #8 
 
 “Oftentimes if they live in a small community, [people living with HCV] feel isolated and 
 so then they end up feeling like they’re contaminated and they don’t like that feeling…I 
 hear a lot about isolation and they feel “dirty” and they have something awful.”  – KI  #8 
 
 “People just need to see people as people. I mean, people think that if they’re taking 
 prescription drugs and they’re abusing them that,“oh yeah, it’s fine because they’re 
 prescribed.” That’s just as much of an addict that’s using street drugs and putting them 
 in their arms with a needle.”– KI  #6 
 
 “The social effects, a lot of people are unable to work during that period of time. I’m 
 sure that’s pretty hard on them.” – KI  #7 
 
 “Social and psychological, I guess I would, well, outside of the stigma, you just can’t do 
 anything outside of the treatment because you are so sick.” – KI  #3 
 
The stigma is not only found socially, but also in the medical field. Most key informants 
mentioned how physicians treat HCV patients poorly because of the “IV drug user” stigma that 
HCV diagnosis carries. Key informants also indicated that physicians tend to be more 
judgmental about how the patient contracted HCV based upon physical appearance. According 
to one key informant, if the patient has tattoos, the physician has likely already decided how the 
virus was contracted. 
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 “[HCV patients] get treated horrendously by the medical people…medical people need 
 to back off and start remembering why they’re here. If they’re here to make the big bucks, 
 they should be a plastic surgeon in Hollywood, not working with the general public.” 
 – KI  #1 
 
 “The doctor…didn’t even look at [the person] and didn’t even acknowledge that [the 
 person] was even there…he just looked down at his clipboard and said you’re 
 positive to HCV…Of course, [person’s name] was wearing  short sleeves and you could 
 see all his tats. You know? He probably made his opinion right there, off of that.”  
  – KI  #4 
 
  
Theme 3: Psychological Effects of Living with HCV 
 
Regarding individuals who are diagnosed with HCV but are not receiving treatment, most key 
informants stated that HCV diagnosis is a psychological struggle. This is not only because of the 
diagnosis of a life-threatening disease, but also because people may be co-dealing with addiction.  
 “When you hear positive, that’s the only thing you hear after that. You don’t hear 
 anything else. You just think that you’re dying the next day.” – KI  #4 
 
 “[People living with HCV are] dealing with addiction issues at the same time and there’s 
 stigma within the drug culture and that makes it worse for them.” – KI  #3 
 
 “[People living with HCV] can’t feel good. The whole, “I made a mistake” thing really 
 weighs on [them]. [They] feel damaged for sure.” – KI  #6 
 
 “Psychological is so caught up in that drug world. Some of them are just…they have 
 their own little world. HCV and drugs just go hand in hand. It’s just crazy.” – KI  #2 
 
 “I think a lot of people think, “Oh, well, I’m already infected, I might as well keep doing 
 what I’m doing. Because I wake up in the morning and I feel like crap. I should do 
 another shot. Or, this is really depressing me. I’m going to leave your office and go get 
 high.” – KI  #5 
 
 “I think the psychological effects are probably that of having a chronic disease. They’re 
 really not sure of what kind of relationships they can have with people and how it can be 
 spread and telling somebody that they have HCV. Or, they’re in the drug world and not 
 wanting to share that information with the people you’re sharing works with.” – KI  #7 
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Theme 4: Physical Effects of HCV Treatment 
 
One key informant, who is a health care professional, shared the following information about 
HCV treatment. The largest side effect of HCV treatment is that the Pegylated-interferon (Peg-
IFN), one of the drugs in the triple therapy treatment regimen, can cause depression in many 
patients who previously did not have depression. One key informant who treats people with 
HCV mentioned that people receiving HCV treatment can experience upset stomach; 
hemorrhoids; overall dryness of the eyes, mouth, skin and hair, and loss of hair. It is also 
possible to develop vasculitis, which causes inflammation of the blood vessels in the back of the 
eyes. Without stopping Interferon use, blindness can occur. Additional side effects of treatment 
include autoimmune disorders such as Lupis and Rheumatoid Arthritis. Essentially, one’s 
immune system does not function optimally when one is undergoing HCV treatment. 
 
 “The physical effects are unbelievable. They are so sick and they can’t function for 6 
 months.” – KI  #3 
 
 “Oh man, it’s tough. I mean, people think they feel bad with HCV and then you watch 
 them go through treatment” – KI  #5 
 
 “It’s really hard, physically, to make it through the treatment…I mean it’s difficult even 
 for someone who is not using, but if they’re using at all, either alcohol or drugs, it would 
 be very difficult. Or if they had any psychological issues at all, it’s very hard to make it 
 through treatment. ” – KI  #7 
 
 “[People receiving HCV treatment] don’t like that they get fatigued, that’s number 
 one…You basically peel the ban- aid off of the immune system, so sometimes these things 
 are there, but they were able to be in-check by your immune system, but [on the 
 medication] they can flare up. You can have significant trouble. The list goes on and on.” 
 – KI  #8 
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Theme 5: Psychological Effects of HCV Treatment 
 
As most key informants agreed, depression is the most common psychological side effect of Peg-
IFN. Because Peg-IFN is one of the three treatments in a triple therapy HCV treatment regimen, 
all individuals receiving HCV treatment are at risk of developing depression. A few key 
informants stated that the side effects of HCV treatment are so terrible that it may not even be 
worthwhile for some to go through treatment. People with HCV can still live a relatively full life 
without treatment if they take care of themselves by abstaining from alcohol and drugs, eating 
healthfully, and exercising. 
 “Just from treatment, from interferon and that, the side effects are psychological, they 
 are tremendous.” – KI  #1 
 
 “Psychologically, you know people have to be tested to make sure they’re not suicidal 
 before they go on it…treatment is awful.”  – KI  #3 
 
 “Because the therapy’s so hard with suicide and depression…and pains and aches and 
 side effects, it’s constant. Most of the time there’s nothing you can do other than wait it 
 out.” – KI #2 
 
 “I’ve seen people be really depressed throughout treatment. It’s not something you just 
 ignore…they think about the behaviors they did to get them there and they feel badly 
 about themselves.” – KI  #5 
 
 “The psychological effects…unless they have a really strong support system going 
 through treatment…I think a lot of them don’t make it through.”  – KI  #7 
  
 “Interferon has a black box warning that it can cause depression in 25% of patients who 
 are treated who have never been depressed. And, certainly if you have underlying 
 depression, it can exacerbate that, so the most important thing is that if you’re treating 
 someone, the number one thing is to monitor for that because it can develop in 
 anyone…if they have a history, they must be stable before starting treatment.” – KI  #8 
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Section 4: Barriers to HCV Treatment 
Theme 1: Treatment Costs 
 
Although one key informant reported that there are ways for those who cannot afford HCV 
treatment to obtain it, most key informants reported that the treatment costs are a large barrier for 
many people seeking HCV treatment. The new medications, telaprevir and boceprevir have 
significantly increased the cost of treatment. This leaves those without money for treatment with 
few, if any, options. As one key informant reported, the treatment itself is only the start of the 
costs; other costs are incurred from lab visits, blood transfusions and other medications used to 
subdue the side effects of HCV treatment. However, it’s still possible for those who cannot 
afford treatment to live a relatively full and healthy life by eating right, exercising and staying 
sober. 
 “So, the barriers for treatment…it’s always the money thing…I think the old treatment 
 was 30,000-40,000, now they’re talking about 70,000-80,000 because of the new med.” 
 – KI #2 
 
 “When you’re giving somebody a positive and you have nothing to offer them, that’s 
 hard. That’s hard for the person giving the results and it’s hard for the person that’s 
 receiving it to know here’s this disease I have and there’s nobody that can help. There’s 
 no free treatment, there’s no treatment that [they] can afford or qualify for…[they] fall 
 through the cracks on all these programs, so yeah that makes it difficult.”– KI #4 
 
 “Everyone I know who is HCV positive is not going through treatment. Whether it be 
 addiction treatment or treatment for their HCV. I have some clients who do try to eat 
 better, exercise and that’s fine for them.” – KI #6 
 
 “Well, the positives that we had in our groups that had treatment…it was really hard 
 and expensive. And, a lot of them didn’t even qualify to get treatment and so it’s kind of 
 hard on them to know they have a disease and there’s nothing they can do about it.” 
   – KI #4 
 
 “Right but number one, the treatment is SO expensive.”   – KI #5 
 “[HCV treatment is] really expensive. So, unless they have a payer source, there’s really 
 not a good way to get those people treated.” – KI #7 
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 “If you’re on triple therapy and you go for 48 weeks, it’s about $85,000 for just the 
 drugs. The telaprevir itself is taken every day for 12 weeks and it’s about $3,000 per 
 week. It’s tremendously expensive, but that’s only part of it because you have to have lab 
 work, most often every week for the first 3-4 months and that’s expensive. Sometimes you 
 have to go on other drugs to support your blood count, just like chemotherapy patients 
 do. Those are very expensive. Blood transfusions sometimes, that’s expensive.” – KI #8 
 
Theme 2: Lack of Knowledge 
 
Key informants also reported that the lack of knowledge of the disease process in addition to 
where and when to seek help is a barrier to receiving HCV treatment. Additionally, those seeking 
HCV treatment do not realize that it is a large time commitment and requires lots of support from 
family and friends. This lack of knowledge may lead individuals to avoid treatment when they 
may need it. 
 “So, the barriers for treatment…it’s always the money thing. And the knowledge thing. 
 Where do you go to get it done? Do you have support? Will you be able to do it on your 
 own?”– KI #2 
 
 “But I think a lot of them think, “I’m going to go, it’s going to be quick and easy.” Most 
 of them are single parents with 2-3 kids. If you’re feeling good, now would be a good 
 time for treatment, but you have to think, you’re going to get sick. You may have to stop 
 work. You need to have support. People get suicidal, and dah dah dah…it’s complex.”  
 – KI #2 
 
 “I also think with their level of education about the disease process too, they may not 
 know the disease progression and what the options are and you know, some are really 
 scared.” – KI #5 
 
 
Theme 3: Treatment is Difficult 
 
In addition to the expense, the side effects of treatment lead people infected with HCV to decline 
treatment. As stated earlier, a person must be free from addictions, committed to following a 
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stringent, complex and time consuming treatment regimen, and be prepared to face considerable 
physical, emotional and social consequences of being treated for HCV. 
 “Some people get really sick from the treatment at may not have been sick before. Why 
 would you want to do it if it’s going to make you feel like shit?” – KI  #6 
 
 “They said they’d rather have the disease than go through treatment.” – KI #3 
 
 “Truth be told, there’s people that don’t want treatment because they don’t want to give 
 up their habit. So, if they have to give something up, forget about it, they’d rather die. 
 I’ve watched people going through treatment who are at the very end, but they are so 
 seriously considering stopping that treatment because they feel SO bad.” – KI #5 
 
 “My checklist for patients to be able to be treated is that they have to be in enough of a 
 socially and psychologically stable situation in order to tolerate the treatment and do the 
 follow up and comply with the things we recommend. So, if they don’t have a support 
 system or a place to live or they’re still using or their psychiatric history, they’re 
 obviously not ready to be treated yet. So, the barriers I would say number 1 is that they 
 need to be in a situation where they can devote up to a year to this treatment.” – KI #8 
 
 
Theme 4: Lack of Access to Treatment 
 
Lack of access to treatment was identified by key informants as another barrier to HCV 
treatment. One key informant reported that there are only about four places in Montana that 
provide HCV treatment because it is such a specialty area. Therefore, most people who do not 
reside in the larger cities in Montana generally have to travel to receive treatment. 
 “I also think that depending where you are within our state, it’s not a simple process. 
 You might be traveling to get to the next city that has a doctor that can treat you...a lot of 
 times people have to drive to get [treatment], so that’s an added expense. Most people 
 don’t have that luxury. It’s a big barrier.” – KI #5 
 
 [There is a] lack of providers who are doing [HCV treatment in Montana]. Most clinics 
 won’t take it on because there’s so much hand holding in the process now. And that’s 
 mainly dealing with the psychological issues of the people who are on the medication…it 
 is so difficult [to find a provider].”– KI #7 
 
 “The one big barrier I forgot to mention is access to treatment. There aren’t a lot of 
 providers that are doing it; it’s such a specialty area…Patients are sometimes treated by 
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 gastroenterologists for the liver disease part, but sometimes treated by infectious 
 disease…but [HCV] is also better suited to an infectious disease department.”– KI #8 
 
Theme 5: HCV is Slow-Progressing 
 
The slow progression of the disease was identified by the key informants as yet another barrier to 
HCV treatment. This is because it is possible to live a good life without HCV treatment. As some 
key informants reported, it is possible that once a person is infected, he or she may not 
experience symptoms of the infection until twenty years down the line. Consequently, HCV is 
not perceived as life threatening as HIV/AIDS.  
 “Most of them know treatment is hard and complicated. They don’t have money, so if 
 you’re not doing drugs anymore, the best thing you can do is to stay off of the drugs. 
 Don’t drink. Your liver will last 20-30 years if you’re not having complications.” –KI #2 
 
 “It depends on the person and the rest of their health and lifestyle changes. I’ve watched 
 some people progress very quickly and most people do great. They go years and years 
 and they don’t even know they have it…But eventually they feel so badly and figure it out. 
 And they say, “that was years ago that I did that.” –KI #5 
 
 “People aren’t going to get sick from HCV until about 15-20 years down the line. So, for 
 some of them, they’ve outgrown the behaviors that got them the HCV. Some of them 
 haven’t, but a lot of them are shocked when they end up with HCV from something they 
 did 15-20 years ago.” –KI #7 
 
 
Theme 6: Must Be Clean and Sober Before Starting Treatment 
 
Most key informants indicated that people seeking HCV treatment must be clean and sober 
before starting the treatment. Using alcohol and drugs while receiving HCV treatment inhibits 
optimal treatment results. This can be a large barrier to HCV treatment for people living with 
HCV who are also facing addiction. Co-dealing with HCV and addiction can be a major struggle 
for many, which is why individuals who desire treatment should first conquer addiction before 
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beginning the treatment regimen.  
 “When you say, you can’t even have a beer…you really need to be good to your body. 
 You need to be clean and sober before you can start this process. And, for the folks I 
 work with, it’s pretty overwhelming. We try to get them clean and sober before they can 
 even consider treatment. It’s baby steps… – KI #5 
 
 “Yes, [people must be clean and sober before starting HCV treatment] because what 
 you’re doing with treatment, if you’re insulting your liver everyday while you’re trying to 
 get your liver healthy.” – KI #7 
 
 “[People wanting HCV treatment must be sober] for at least 6 months, yes. There are 
 some people that will treat intermittent drug users, IV drug users, I’ve heard of that but, I 
 would say that’s pretty rare.” – KI #8 
 
Theme 7: Stigma and Lack of Knowledge Among Physicians 
 
Most key informants mentioned that physicians often contribute to the stigma felt by people who 
are infected with HCV. This stigma appears to be related to both the lack of treatment options 
available for physicians to prescribe to their HCV positive patients, and the association between 
HCV and injection drug use. However, as many key informants pointed out, HCV is not 
specifically a “junkie” disease. Moreover, a few of the key informants indicated that general 
physicians do not know how to properly treat HCV and therefore end up mistreating patients or 
not referring them to the correct specialist. This is a large problem in Montana due to the few 
specialists available.  
 “I hear that from a lot of the Hep C people in [Montana City]. They get treated 
 horrendously. You heard it today, they get treated horrendously by the medical people.”  
 – KI #1 
 
 “[The mother of my two children has] never been an IDU, she doesn’t use drugs, she 
 does drink, or did drink, she doesn’t much now, she got Hep C from a blood transfusion, 
 from childbirth, she had a cesarean…she went to the doctor first time and the doctor 
 insisted that she was a drug user and told her to leave his office.” – KI #1 
 
 “Infectious disease docs usually take care of the treatment stuff…and they’re getting 
 better at it, but for a while there, people wouldn’t even talk about it. But, again, it goes 
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 back to education because some of the docs don’t always know and they refer them on 
 and so, Montana’s behind the times, isn’t it?” – KI #3 
 
 “I’ve seen a lot of patients and they tell me they went to see someone and they were 
 handed a prescription and told, “I’ll see you in 3-6 months or something,” when some of 
 these patients should be seen on a weekly basis…I think it’s a lack of awareness and 
 education and [the physicians] don’t know what to do with it. They don’t know how to 
 interpret the test results. I think a lot of people are still out there thinking that there’s 
 nothing to be done for it or patients who have [HCV] are all crazy and nuts and drug 
 abusers or whatever; there’s a lot of stigma.” – KI #8 
 
 
Section 5: Barriers to HCV Prevention  
Theme 1: Lack of Education 
 
Key informants reported that the main barrier to HCV prevention is lack of education among the 
public. Most key informants agreed that people simply aren’t educated about HCV and how it’s 
transmitted from person to person. As previously mentioned, a part of this lack of education 
originates from the school system. Children in school are not taught about HCV and the ways it 
can be transmitted.  
 “Well, barriers for everything are the same. It’s [that] people don’t believe they’re at 
 risk or if they do believe they’re at risk, they don’t care because the behaviors they’re 
 engaging in are far more pleasurable than not…People need to be educated about HCV. 
 People don’t even know about HCV. They’re inundated with HIV until they can’t even 
 hear that anymore and so become apathetic….HCV, people just don’t talk [about].”  
 – KI #3 
 
 “I really think people have a lack of knowledge. The more people I see that are positive… 
 I get it over and over and they say, “well, I used my own needle.” I talk to them about 
 cooking and cottons and the whole schpiel and we do the visual and I tell them, “well, 
 when you put the plunger back down, what do you think you’re getting back in there?” 
 And it clicks.” – KI #5 
 
 “People not knowing how it’s spread I think is a another big factor. Young kids not 
 knowing. It’s just not something we teach. I don’t think a lot of drug users know that if 
 you’re sharing the straw, the works, the spoon, the cotton, that you can also spread it that 
 easily. I don’t think they’re aware of that. So, I would say lack of education.” – KI #7 
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Theme 2: Lack of Funding 
 
The lack of funding for HCV prevention was also reported as a big barrier to prevention efforts. 
Government funding for HCV prevention and education in the state of Montana is 70% less than 
the funding for HIV prevention and education. Many key informants mentioned that it is 
impossible to buy the necessary number of HCV tests with that money, consequently, it is a 
struggle to identify individuals who are infected. Furthermore, lack of funding affects the state’s 
ability to hire outreach workers who, in general, are on the front lines in regard to identifying 
individuals who are most at risk for infection. Without funding for testing and without funding 
for outreach workers it is difficult to acquire an accurate picture of how HCV is impacting the 
state of Montana. 
 “That’s how [getting the numbers is] going to happen is outreach. Frontline, basic stuff 
 is outreach. Get people to get tested and that’s where you’re going to find the people that 
 are already Hep C positive.” – KI #1 
 
 “Nobody wants to fund [HCV Prevention] if the Governor’s wife doesn’t have it.” 
  – KI #6 
 
 “There just aren’t enough resources. We get $29,000 for our State from the Feds, to do 
 HCV education…You can’t buy a lot of tests with that money, so people can’t even figure 
 out if people are infected. And, if they are infected, how do you pay for treatment? It’s 
 just a vicious cycle.”  – KI #3 
 
 “The funding is so little that there is no funding for HCV…We get less and less every 
 year. ” – KI #4 
 
 “I think more money should be available to do free outreach testing for Hep C. We do 
 free testing at the pre-releases and jails but our resources are very limited. We fund 
 these programs through county dollars now. With the availability of the rapid test we 
 could do way more testing if we had the funding to buy the tests.” – KI #7 
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Theme 3: Stigma 
 
Many key informants mentioned that stigma is a significant barrier to HCV prevention. This is 
because people who are infected with HCV and are knowledgeable about the ways it is currently 
and most commonly transmitted, such as medical practitioners, don’t want to talk about it due to 
its association with injection drug use.   
 “I think a barrier too is the stigma, because people don’t want to talk about it. People 
 who do have it certainly don’t advertise it. If people do find out about it, then they have to 
 deal with the stigma and discrimination and they stop talking about it. You know, we 
 need more people talking about it.” – KI #3 
 
 “I think a big reason why we don’t hear about it or talk about it is because people who 
 have it are people that nobody cares about. They’re low income, people of color, they’re 
 in prison/jail, they’re in and out of treatment centers, they’re drug users, you know? All 
 these undesirables …people don’t care until they’re personally affected. Until they get it 
 or until a family member dies from it.” – KI #6 
 
 “There’s a lot of stigma, there’s a lot of hesitation to talk about it, hesitation to screen 
 for it in the clinic, “well, I’m sure she doesn’t have that..”, well, let me tell you, if you 
 looked at my waiting room, you would not be able to pick out those patients. Some, yes.” 
 – KI #8 
 
 “You can belong to this culture until you’re positive in HIV or HCV and then you’re 
 dumped out. I think that causes people to shoot up even more. To anesthetize themselves 
 from loneliness…I know people who are very well known in communities and who are 
 very functional…who are socially acceptable because they got HCV via a needle stick or 
 a transfusion. So, they’re fine. But, if you got it using drugs, because you were an illicit 
 user, it’s totally different. And psychologically, it’s the same. People who got it through 
 needle stick…it’s almost like saying, “oh, that’s a valid way of getting HCV,” rather than 
 someone getting it otherwise.” – KI #3 
 
Theme 4: Few Prevention Options 
 
Currently, there is only one prevention option available to those who fall under the high-risk 
category of sharing needles to inject drugs or other substances. That prevention option is not 
sharing needles.  Unfortunately, needle/syringe exchange programs are illegal in Montana. 
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Despite this law, there are currently a few underground needle exchanges in the state. Due to the 
fact that needle/syringe exchange programs are illegal in Montana, there are no advertisements 
for these underground exchanges; they are mainly known through word of mouth.  
 “We do trainings, just to educate about HCV, HIV and STDS. So, those are counseling 
 and testing trainings. We also do regional trainings throughout the state. So, from here, 
 prevention services in communities…there just aren’t a lot.” – KI #3 
 
 “The only thing I can think of [regarding prevention services] is the underground 
 exchange. That’s offered in 4 major cities; [it’s] still on a limited basis. Someone has 
 to know [about it]…it spreads by word. “ – KI #4 
 
 “So, there’s no prevention services that I know of. I mean we’ve done some education 
 campaigns in the youth detention services about it, but other than that I don’t know of 
 any.“ – KI #7 
 
Section 6: Ways to Improve HCV Prevention 
Theme 1: Media 
 
Many key informants mentioned that media is an excellent way to improve HCV prevention. 
With optimally targeted media campaigns, HCV prevention could be highly successful. Media 
outlets that key informants mentioned include: social media platforms such as Facebook and 
Twitter, public campaigns and public service announcements. 
 “Social media can do so much. HCV is not a big one that people are afraid of though. 
 People say, “I don’t want to get HIV and I don’t want to have babies.” – KI #6 
 
 “I think a lot of the IV drug users don’t know how easily it’s spread and how it’s spread. 
 Maybe a public campaign on how HCV is spread would be a good one.” –KI #7 
 
 “There needs to be some media. There’s no social marketing at all for HCV, I mean, I get 
 information from the CDC website, but if I was just Joe public, you don’t see nothing. 
 People don’t even know it’s out there. They don’t even know how to get it or how to 
 prevent it.” –KI #2 
 
 “I mean for the people using now, probably public service announcements. You have to 
 reach the intravenous drug use and tattooing populations. Maybe some kind of public 
 awareness campaign targeting tattooing in jails, youth detention facilities, pre-release, 
 treatment facilities.” –KI #7 
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Theme 2: Education 
 
As all key informants reported, the best way to improve HCV prevention is through education. 
Although education can be improved in many ways, most key informants agreed that HCV 
education needs to begin in middle school when kids are most likely to experiment with drug use 
and other risky behaviors.  
 “I think that comprehensive education early on, when folks are really young. I don’t think 
 I heard about HCV until I was 20 or 21…I think talking about it earlier would help. I 
 think it needs to start in at least the 8th grade. Junior-high probably. We have lots of 
 young folks who inject…so, the sooner, the better.” – KI #6 
 
 “I would like to see more education about injectable drug use. It’s not just about, “don’t 
 do this and don’t do that,” but you really need to talk about injecting and how harmful it 
 is and what it can do to you in your future. Not only do we need to talk about STDs, birth 
 control, and puberty, but we need to talk about putting a needle in your arm and 
 yet…these kids are only 13. When I talk to them, they’re like, “I wish somebody had told 
 me this when I was younger.” That’s what they all say. But, it’s using that knowledge and 
 saying, oh I would have been a little more careful using.”  – KI #5 
 
 “I think education is so key. I don’t understand why there’s not so much more emphasis 
 on it. We’re so reactive versus proactive…I think standardized testing is good. People 
 are like, “how can we afford it?” Well, if we did education beforehand, then we 
 wouldn’t have to find a reason to afford it later.” – KI #6 
 
 “If you look at research in anything like this, educating people is the best way to reduce 
 the risk of trying to reduce the behavior we’re trying to prevent. We still get caught up in 
 the thinking that by talking about it, we’re going to promote it.” – KI #5 
 
 
Theme 3: Increased Funding 
 
The majority of key informants reported that increased funding needs to be available for HCV 
prevention. More funding would mean more education, which would mean increased HCV 
awareness and de-stigmatization. Furthermore, if there was more funding for HCV prevention, 
there would also be a greater availability of HCV tests. This would lead to an increase in the 
number of outreach workers who, in many cases, are able to identify and test individuals who are 
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most at risk for infection. Key informants also mentioned that without money for testing there is 
no way to determine how many people are infected with HCV. Consequently, without the 
numbers of people who are infected, it is difficult to attain funding. Finally, without funding, 
there is no prevention and without prevention, there is a greater prevalence of disease. 
 “If the [HCV] numbers were right with the epidemiologist, if there was a way to track it 
 like we do with HIV. I think some of the big wigs would take a look and say, “hey we 
 need to move our attention to HCV.” – KI #4 
 
 “Getting more people on board, educating more people, more money, you know the state 
 doesn’t kick in anything for HIV, HCV or STDs. So, if people in MT really wanted to 
 make a difference, then there would be a lot of lobbying for it.” – KI #3 
 
 “We need more money!” – KI #2 
 
Theme 4: De-Stigmatization of HCV 
 
De-stigmatization of HCV can happen in many ways as several key informants reported. The 
first is through education; by educating not only children in school, but also adults about HCV 
and its transmission routes, much of the stigma can be removed. Another way key informants 
indicated that HCV could be de-stigmatized is through raising awareness. Raising awareness 
about HCV can be done through media campaigns that include personal stories. As one key 
informant mentioned, the public is always more affected by media that includes personal stories, 
rather than those that do not.  
 “People are just really judge-y. I don’t even know where to start aside from just talking 
 to people about it, you know? Conversation is the best way for sure. ”– KI #6 
 
 “We need more people talking about it. You know, I have lived with this, but here’s how I 
 got it and I don’t want you to get it. How could these barriers be reduced or eliminated? 
 Well, education is huge and de-stigmatizing it. Stigma just gets us is so much trouble.” 
 – KI #3 
 
	  
	  
63	  
 “I guess [people] need to step up and say it more. Instead of it just being tattooed joe 
 over here! More people need to share how they got [HCV] - ones that aren’t drug 
 users.”– KI #4 
 
 “I think raising awareness and talking about it so that the stigma is less [will help to de-
 stigmatize HCV].” – KI #8 
 
Section 7: Ways to Improve HCV Treatment 
Theme 1: Decrease the Cost 
 
As reported by a key informant who treats individuals with HCV, 48 weeks of triple therapy 
HCV treatment costs about $85,000. This price does not include the extra costs of lab visits, 
blood transfusions, if needed, and medications to assuage the side effects of HCV treatment. 
Although this key informant mentioned that there are ways for those who can’t afford treatment 
to get it, the majority of key informants reported that most people with HCV do not qualify for 
those options and therefore cannot afford treatment. Thus, the majority of key informants agreed 
that it would be beneficial to have reduced treatment costs. 
 “[Treatment] could be less expensive. Make it more accessible.” – KI #6 
 “Make [treatment] free! Do it on a sliding fee scale. It really comes down to money for a 
 lot of people. It’d be great if there would be easy clinics. Like the methadone clinic, they 
 go the HCV clinic. I think money is the biggest thing.” – KI #5 
 
 
Theme 2: Increase Accessibility of Treatment 
 
As previously stated, there are only four medical facilities in Montana that offer HCV treatment. 
Most key informants indicated that it would be advantageous to increase availability to treatment 
in order to eliminate the accessibility barrier.  
 “Making it more accessible for sure; both financially and more people offering it.” 
  – KI #6 
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 “Just make [HCV treatment] more available.” – KI #7 
 
Although only a few key informants mentioned Project ECHO (Extension for Community 
Healthcare Outcomes), it is becoming a more common way to offer HCV treatment in Montana; 
it could also be used to lessen the accessibility barrier to those needing HCV treatment. Using 
interactive video, the Northwest Project ECHO offers weekly online clinics, providing real-time 
clinical consultation between community providers and a multidisciplinary panel of experts, 
including Infectious Disease, Psychiatry, Family Medicine, Pharmacy, Nursing, and Case 
Management (Northwest AIDS Education and Training Center, 2013). Essentially, Project 
ECHO allows less-experienced primary care providers in Montana to treat more complicated 
diseases, such as HCV. Project ECHO has a great potential to increase accessibility to HCV 
treatment and therefore diminish the accessibility barrier to HCV in Montana. 
 “The reason that I could treat patients and do so reasonably comfortably was because I 
 was tied in with the Echo Program. Basically, what it is is a grant-funded panel of 
 experts that allow you to treat a complicated disease with expert consultation as a less-
 experienced primary care provider, so this was run by a hepatologist at the Unviversity 
 of Salt Lake. On his panel he had a psychiatrist, a pharmacist, and so every week you can 
 present cases and there’s anywhere from 5-7 different sites that come on telemedicine, so 
 it’s a sounding board, so then you can get some help. Like, “okay, my patient’s doing 
 this, what do I do now?” Because these are people who have been treating it and using 
 these drugs for longer. You can’t have experience with the drugs until you have 
 experience with the drugs. That is essence is trying to open up access so people don’t 
 have to drive 400 miles to [Montana City] and I don’t have treat someone who lives 400 
 miles away.” – KI #8 
 
	  
	  
65	  
Summary Reports 
 
Three key informants distributed summary reports to HCV positive individuals from various 
counties and towns in Montana. On March 25th, 2013, key informants were sent pre-addressed 
and stamped envelopes that contained the following items: an IRB-approved participant consent 
form (see Appendix E), recent epidemiological data from 2010-2012, $30 cash for participation 
and a summary report. Within the summary report, there was also an optional demographic data 
form for participants to complete (see Appendix G).   
 
One key informant requested the ability to individually mail summary report to four participants. 
In this case, the key informant received four large, pre-stamped envelopes with one smaller, pre-
addressed and stamped envelope per large envelope. The participant used this smaller envelope 
to send the summary report back to the researchers. This packaging allowed the key informant to 
mail the larger, pre-stamped envelope to the participant and enabled the participant to easily 
place the summary report in the smaller envelope and mail it back to the researchers.  
 
Each summary report consisted of five sections: 1) Transmission of Hepatitis C; 2) 
Environmental Factors that Contribute to HCV; 3) Effects of Living with HCV and Effects of 
HCV Treatment; 4) Barriers to HCV Prevention and Treatment; and 5) Ways to Improve HCV 
Prevention and Treatment. After each section, the participant was asked to respond to the 
following questions: 1) Are there statements in this section that you believe are inaccurate or 
with which you disagree? If yes, can you briefly explain what you would change? and 2) Is there 
any other information you would like to add? Additionally, participants were asked to fill out an 
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optional demographic form (see Appendix G) that included four questions about: gender, age, 
annual income level, and region of the state that is currently inhabited.  
 
Once the summary reports were returned to the research team, the research assistant numbered 
all reports and typed out all comments. Analysis of the report comments involved the same 
process as the data analysis of the key informant interviews. After following Ulin et al.’s 
qualitative data analysis process and completing the investigator triangulation, 17 themes 
emerged out of 6 sections. The 6 sections correlate with the 5 sections in the summary report and 
include an additional section for miscellaneous responses that could not be categorized into a 
previous section. In order to enhance reading ease, extraneous words such as “like,” “you know,” 
“yeah,” etc. and other words that affected the quotation were removed.  
 
Results of the summary reports are presented below. 
Demographic Data 
 
In total, 47 summary reports were mailed and 45 were returned by the requested return date, 
April 15th, 2013.  Three individuals chose to not fill out the optional demographic data form. 
Therefore, the demographic tables below represent the responses from 42 individuals who 
completed the form.  
 
Demographic data was analyzed using SPSS 21. Frequencies were run on the data to determine 
the number of respondents in each category (ie. age, gender, etc.) and the percentage of 
respondents representing each category. The following tables illustrate the findings: 
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Table 2 Sex of HCV Positive Participants 
 
 Frequency Percent 
Male 27 64.3 
Female 15 35.7 
Total  42 100.0 
 
Table 3 Age of HCV Positive Participants 
 
 Frequency Percent 
18 to 24 8 19.0 
25-34 10 23.8 
35-44 9 21.4 
45-54 10 23.8 
55-64 4 9.5 
65-74 1 2.4 
Total  42 100.0 
 
Table 4 Annual Income of HCV Positive Participants 
 
 Frequency Percent 
Less than 6,000 11 26.2 
6,000-10,000 10 23.8 
10,001-20,000 9 21.4 
21,001-35,000 5 11.9 
35,001-50,000 3 7.1 
50,001-75,000 4 9.5 
Total 42 100 
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Table 5 Region of the State of HCV Positive Participants 
 
 Frequency Percent 
Region 1 0 0.0 
Region 2 1 2.4 
Region 3 15 35.7 
Region 4 14 33.3 
Region 5 12 28.6 
Total 42 100 
 
From the data, it is evident that most respondents were male (64.3%), ages 25-54 (69%), who 
make less than $20,000 annually (71.4%) and live in regions 3 and 4 of the state (69%). 
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Emergent Themes from Summary Reports 
 
Section 1: HCV Transmission 
Theme 1: Transmission Misconceptions 
 
Although participants were given the most current, accurate transmission routes according to the 
CDC, HCV Advocate, as well as Key Informants, respondents had misconceptions about HCV 
transmission routes such as transmitting HCV through hot tubs, sex and toilet seats. Although it 
is possible to spread HCV through sexual contact, the risk is believed to be very minimal. 
 “Even sex can spread HCV. But I didn’t know razors or hygiene can spread it too. There 
 was a lot of information about it I did not know.” 
 
 “Hepatitis C can be transmitted through open sores, IV, hot tub, or public sauna from 
 another person or germs in water.” 
 
 “I would like to know if I am putting my dentist at risk—can HCV be transferred 
 through insect bites?  How about bodily fluids such as sweat?” 
 
 “Remember you can get it from a toilet seat!” 
 
Section 2: Environmental Factors that Contribute to Infection with HCV 
Theme 1: Poverty 
 
 
Although Key Informants believe poverty to be a main contributor to the spread of HCV, the 
summary report respondents felt very differently. The majority of respondents indicated that 
poverty is not an environmental factor that contributes to HCV infection because HCV can affect 
everyone.  
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 “To be clear: poverty is the result of drug use among those using drugs. Drug users don’t 
 use drugs because they are poor. People who value work don’t get high. To the extent 
 that HCV is transmitted due to drug use, poverty is the result and not the cause.” 
 
 “I think it’s so dumb to say that only poor people get [HCV]. I think anyone and 
 everyone can get this.” 
 
 “I don’t think that being poor means that poor people have HCV. Disease like this 
 doesn’t discriminate. I feel anyone can get this.”  
 
 “I do not believe poverty has anything to do with HCV-even people who have money 
 share needles, toothbrushes, etc.” 
 
 
Theme 2: Lack of Knowledge and Education 
 
The majority of respondents agreed with the Key Informants about the need for HCV knowledge 
and education early on. Many of the respondents mentioned that substance use and sexual 
behaviors are starting to occur earlier in life and children need to be informed of the risks they’re 
taking before engaging in sexual behaviors or substance use. 
 “Children should be taught about all these diseases in 4th grade. Drug use is often 
 beginning in 4th grade. This should be a requirement of all schools, motels, hotels, 
 restaurants as well as bars. I know for a fact that these places have no knowledge of how 
 to deal with HCV or HIV/AIDS.” 
 
 “Try to tell kids in schools this info—I started when I was 14.” 
 
 “They should start teaching kids by the 6th grade. In my experience, in the life I’ve lead of 
 using IV drugs, everyone is getting even younger as they start using.” 
 
 “Maybe reaching out to kids in grades before high school to inform kids who are starting 
 to try drugs and have sex as young as 12 (7th and 8th). [I] informed my son (who now is 
 in high school) as soon as I found out he was having sex last year in 8th grade .” 
 
 “Don’t be embarrassed to ask for help and start talking to kids when they are young. Just 
 say no has never worked—they need to know the truth about how drug use and Hep C 
 can change lives forever.” 
 
 “The end of elementary school is when they should start HCV education.” 
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 “I’ve had hep C since I turned 19. I’ve tried to be 100% informed about Hep C even 
 before I got it, but there’s so much info I didn’t know at the time that I contracted Hep 
 C.” 
 
 
Theme 3: Access to Clean Needles 
 
The majority of respondents agreed that the sharing of dirty needles and works is a large 
contributor to the spread of HCV. Furthermore, respondents recognized that the spread of HCV 
could be minimized if there was greater access to clean needles and syringes. Respondents 
mentioned that PWID are not willing to go out of their way to obtain a clean needle and they will 
inject regardless of using a clean or dirty needle. Therefore, the best way to minimize 
transmission of HCV is to make clean needles easily accessible. 
  “Make syringes available easily. In practice, restricting supply of syringes rarely 
 reduces drug use nor does it encourage an IV user to use the drugs in another way. The 
 choice for an IV user is only clean vs. dirty.” 
  
 “If pharmacies made clean syringes easy to buy I know new cases would decrease at 
 least a little.” 
  
 “We need ways to exchange rigs that are dirty. Bring the community to understanding 
 that drug addicts are going to get their fix with or without clean rigs. If it is hard to 
 obtain rigs, then we won’t take the risk.” 
 
 “If you are an addict and there is dope and only one needle, you’re going to use it no 
 matter what. Don’t make it so hard to get clean needles.” 
 
Theme 4: Prison System 
 
The majority of respondents agreed that there is a high rate of HCV in prison system. Many 
indicated that this is due to the fact that it is not possible for those in prison to obtain clean 
needles for tattooing and/or injecting drugs.  
 
 “I agree that high rates are in the prison systems and not enough is done to teach 
 inmates about not spreading this disease.” 
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 “The prison system needs to hear from the pos Hep C inmates. If there was some way to 
 get safe tattooing ink, guns in prison then the rate would go down. Tattooing is big in 
 prison [and] so is drug use, but clean tattoo [needles and] works would help!” 
 
 “In prison, tattoo is a big thing. We need to see if prison staff will let us tattoo in a safe 
 place and not reuse needles or ink. When a guy walks in to a prison and has money and 
 wants tattoos, he is taking a big risk for Hep-C.  It’s blood to blood and if Hep C can live 
 in a rig for 43 days it’s likely [to be the] same in ink and or a tattoo gun.” 
 “I caught Hep C while in the prison system. I got tattoos but even though I took extra 
 steps to help reduce the risk I got it. The artist stuck himself and kept going.” 
 
Further adding to the high infection rate, respondents agreed that it is near impossible to even be 
tested for HCV in prison, let alone receive treatment.  
 
 “Those that are in jail do not receive any form of treatment for Hep C if it is already 
 noted in their file…they go to prison [and] they do not get proper medical treatment in a 
 timely fashion or they don’t get any treatment of any kind.” 
 
 “I have personal experience with the hurdles to try to get treated in prison, which  are 
 almost insurmountable. I think treatment needs to be more available and cheaper to 
 the poor.” 
 
 “Prison—treatment is almost non-existent. Long terms in prison can be a death sentence. 
 Prison environment is the best place to contract Hep C.” 
 
 “I have requested to be tested for HCV while incarcerated more than once. Never have 
 been, was told unless something is going wrong then they won’t test. They (nurses) told 
 me they only test 2x per year.” 
 
 
Section 3: Effects of Living with HCV and Effects of HCV Treatment 
Theme 1: Physical Effects of HCV Treatment 
 
The majority of respondents agreed that the physical effects of HCV treatment are tremendous. 
Many mentioned fatigue, depression and psychological issues as the most common and most 
difficult side effects of treatment. 
 “I can’t comment on the effects of HCV on my body because I was treated with interferon 
 immediately after diagnosis and shortly after infection. Interferon definitely causes 
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 fatigue and depression. Working while undergoes treatment is nearly impossible and the 
 co-pays for all the medicine necessitate working to cover the costs.” 
 
 “I underwent treatment on Interferon Alpha 2A combined with [Ribavirin] and then new 
 drug, telaprevir. I did become depressed, I also wasn’t able to work, couldn’t think or 
 talk right, it was a living hell.” 
 
 “Interferon treatment beat me down. I lost weight and had dizzy spells. I had to stop 
 treatment.” 
 
 “Depression, loss of self worth, being fatigued, experiencing continuous GERD 
 [Gastroesophageal reflux disease], vomiting, feeling nauseated while cooking, 
 experiencing stomach/bowel trouble after eating something or not being able to eat at 
 all.” 
 
 “Being fatigued to the point that I am not able to attend all day events—needing at least 
 1 nap per day just to be able to feel okay.” 
 
 “Depression—fatigue are major in my personal side effects of HCV. Also notably being 
 sober has helped with the process or lack of with my HCV.” 
 
 “In 1992 I had a dear friend taking Interferon and Ribavirin and I noticed a severe 
 personality change. She committed suicide 3 weeks later.” 
 
Theme 2: Social Effects of HCV 
 
The majority of respondents talked about the social difficulties of having HCV. The most 
common sentiments were that they feel like they are a threat to others, they feel isolated, 
hopeless and judged by others. 
 “Definitely agree with the social and mental aspects of the disease, having Hep C can 
 make you feel like a pariah, unclean, like people judge you for it and don’t want to touch 
 you.” 
 
 “I don’t tell people I have HCV because most people back away from me and then want 
 nothing more to do with me.” 
 
 “It’s hard to tell people; they don’t understand and judge you.” 
 
 “I have a self-conscious feeling that having HCV makes me less of a person, a dangerous 
 person to others if I would inadvertently infect someone else…Not knowing any other 
 people living with HCV who could help me by sharing their experience, strength and 
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 hope just reinforces the isolation that I feel every day, knowing I am a danger to my 
 children, husband, and friends…I feel helpless, alone, and devoid of the hope that I will 
 ever feel well again.” 
 
Theme 3: Stigma from Physicians 
 
Many respondents indicated that they felt mistreated by medical professionals due to the stigma 
that is attached to having HCV. Respondents reported that they feel judged by their doctors and 
their doctors just assume HCV was contracted through IV drug use or tattooing. 
 
 “Lack of compassion for the disease from the people that treat you. Calling you a drug 
 user addict.” 
 
 “Medical treatment of addicts is horrible and they are treated very poorly by all medical 
 facilities and their staff as well as dental care from dentists.” 
 
 “I feel like doctors don’t want to help. There is pain associated with Hep C. Can’t seem 
 to get help—also they know what’s good and not good for the liver. What do we pay them 
 for. Bedside manner. And who are they to judge.” 
 
 “People need to have access to proper food, medical, and dental without having to be 
 afraid of being treated like they are nothing but garbage. We are all people with feelings, 
 even if we addicts and poor!” 
 
 
Section 4: Barriers to HCV Prevention and Treatment 
Theme 1: Treatment is too expensive and difficult 
 
The majority of respondents agreed that HCV treatment is too expensive. This serves as a large 
barrier for many and as a result, many who need treatment are not able to get it. 
 “HCV should be affordable (sic) for anyone. And stress treatment above people.” 
  
 “There needs to be scholarships or they need to put the price down because there are 
 people that are asking for help and can’t get it because of the amount (price) this is 
 ridiculous and not fair.” 
 
 “[Treatment] is all so expensive to treat and then no guarantees.” 
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 “I just agree cost and distance is outrageous!” 
 
 “I disagree with the price of treatment…guess I’ll learn to live with it!” 
 
Additionally, respondents indicated that treatment difficulty is another barrier to receiving 
treatment. This is a reason that many who need treatment choose to go without. 
 “I’ve been told at first diagnosed with HCV I was no good to do treatment because of 
 liver damage I’ve done to my liver. Now after a few years the docs told me I could do 
 treatment! But I don’t want to do treatment. My body is in a lot of pain now. Bad 
 headaches and my memory is shot. If treatment makes this worse then no thanks.” 
 
 “Treatment scares me worse than the virus.” 
 
 “Treatment for HIV is relatively easy. HCV is not.” 
 
Theme 2: Lack of awareness among physicians 
 
In addition to the stigma from physicians, respondents reported that the physicians don’t always 
know how to treat patients who are living with HCV. Moreover, it was mentioned that 
physicians were disrespectful about patients’ time and would make last minute decisions about 
tests to order.  
 “Having to ask a doctor to even test me for HCV was a negative experience. The doctor 
 assured me I did not have HCV but would only order the test to put my mind at ease. 
 When the HCV test was positive and all my other blood work was normal, the doctor 
 didn’t know what to do, or where to send me for further information or treatment.” 
  
 “Just the negativity--no follow ups from the doctor. I had reactions to the meds and they 
 did not believe me--my children’s doctor said you’re having a reaction and she wrote 
 me a prescription.” 
 
 “My doctor did a terrible job of attempting to minimize the number of trips I had to make 
 for office visits. He would insist on an appointment, then a blood test and then a follow 
 up to talk about the blood test results. He should have ordered blood tests 2 weeks before 
 the visit and required only 1 trip to the office rather than 2. It took 5 hours round trip to 
 see him. Doubling up the visit adds up over the course of 48 weeks of treatment.” 
 
 “Education of primary care physicians to take the side effects of having HCV are 
 completely addressed—and—treated. They never say that my peripheral neuropathy was 
 caused by HCV. The surgery to remove swollen lymph nodes was not mentioned as a 
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 possible symptom of my HCV status. I can’t get my symptoms treated—and until a 
 symptom results in an ER visit only then does my primary care doctor treat me.” 
 
 “I have no way of knowing if treatment would be an option for me. It seems they want my 
 liver to fail completely before they offer me an opportunity to be treated.” 
 
Theme 3: Lack of funding for prevention 
 
Lack of funding for prevention was found to be a large barrier to prevention. The majority of 
respondents reported that the funding for HCV prevention should be increased to improve 
education and increase awareness about HCV. As respondents stated, by enhancing education 
and awareness, the spread of HCV will decrease over time.  
 
 “There needs to be more funding for front line workers that work to get the word out 
 about Hep C. This disease is far worse than HIV.” 
 
 “I believe that the funding for HCV should be around the same amount of funding they 
 use for HIV, because they both are diseases not matter how minor it may seem to 
 everyone.” 
 
 “Just that it seems that more funding and awareness would be key to stop the spread of 
 Hep C and HIV.” 
 
 “More money is needed through federal and state budget to combat HCV for programs to 
 increase awareness. Awareness should start or target a younger age group.” 
 
 “More money would mean more education on HCV.” 
 
 “I know of the clean works program offered but it would be nice to see some substantial 
 funding of these type of programs so they would be better known about throughout the 
 community.” 
 
Section 5: Ways to Improve HCV Prevention and Treatment 
Theme 1: Increase HCV awareness 
 
The majority of respondents stated that there is a great need for HCV awareness in Montana. 
Many respondents reported that they hear a lot of information about HIV and STDs, but not a lot 
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of information about HCV. They believe that the increase in HCV awareness is critical to 
minimize the number of HCV infections in Montana. 
 “Greater awareness in the community would be highly beneficial” 
 
 “We need more of people out there to stand up speak up. Get off the bunk, couch and do 
 something about Hep C.” 
 
 “You never hear about HCV like you do HIV and other STDs.” 
 
 “The state needs to look at HCV like they look at HIV. HCV has bigger numbers but the 
 state does nothing? I know of a lot of people that can’t hold down a job because of HCV 
 the pain stops them from working.” 
 
 “Education and awareness is critical to fight HCV; knowledge of prevention, 
 contraction, and the spread of the disease among youth is vital I think.” 
 
 
Theme 2: Legalize Needle Exchange 
 
In alignment with previous statements about the lack of access to clean needles, HCV Positive 
participants reported that legalizing needle exchange would decrease the burden of the HCV in 
Montana. The majority of respondents indicated that this is because PWID think more about 
getting a fix rather than the consequences of using a dirty needle to inject. By giving PWID a 
safe place to access needles/syringes such as a needle exchange, respondents believe HCV 
infection rates would decrease.  
 
 “Just want to say again that a needle exchange would be beneficial towards a decrease 
 in the virus.” 
 
 “A needle exchange program is imperative, so users don’t use infected needles.” 
 
 “I feel the lack of a needle exchange is a huge part of the rise of Hep C. A junkie will 
 compromise his safety for that one fix only thinking about the consequences after the 
 fact.” 
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Theme 3: Decrease the cost of treatment  
 
The majority of HCV positive respondents agreed that the expense of HCV treatment is a large 
barrier to treatment. Respondents reported that most people cannot afford treatment and they 
believe that treatment costs should be reduced. They also mentioned that they don’t understand 
why it has to be so expensive.  
 
 “I think the treatment should be cheap to help others. I can save someone’s life if you 
 would just make the cost go down.” 
 
 “I again disagree on the cost for treatment; it is too much money. You could go to college 
 for that amount.” 
 
 “Funding is key. Expense of drugs is most prohibitive element. Exactly why are the drugs 
 so expensive?” 
 
 “Make treatment easier to afford.” 
 
Section 6: Miscellaneous 
Theme 1: Lack of Motivation to protect oneself 
 
The lack of care to protect oneself against HCV also emerged as a theme in the summary reports. 
The majority of respondents mentioned that peoples’ lack of care to protect themselves from 
HCV also contributes to the spread of the virus. This is especially true among PWID, as 
mentioned by respondents, because they are more focused on getting their fix, rather than taking 
precautions. Furthermore, respondents reported that there is a low perceived severity of HCV 
and tend to have an “it won’t happen to me” attitude. 
 “I also believe there are people out there who don’t want to get tested so they just keep 
 doing what they are doing and keep infecting others. There are ones who are so addicted 
 to drugs and just want to get high, and are coming down; they don’t care if they got it.” 
 
 “I could be wrong but from what I’ve witnessed most people know the dangers of Hep C 
 and other blood born viruses, but under certain circumstances, don’t care. Most are 
 more than willing to share “works” when dope is around.” 
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 “There is a large trust factor among injection drug users. They say they are clean when 
 they know they aren’t.  I fall into this category. I believed him.” 
 
 “I am very educated but that doesn’t mean I make the best choices in the heat of the 
 moment. Most of the time I don’t want to take the time to make sensible choices.” 
 
 “Teaching people to care about consequences. I knew about HIV and HCV, I just didn’t 
 care much. I tried to be careful, but had an “it won’t happen to me” attitude. I wonder 
 how I got it and why I don’t have symptoms if I got it 30 years ago.” 
 
 “People think it’s not that bad so it’s not that big of a deal. People need to know the 
 long-term effect of this.” 
 
Theme 2: HCV numbers are much higher than the epidemiological data indicates 
 
Another theme that emerged from the reports was the disagreement with the epidemiological 
data. The majority of respondents reported that the epidemiological data does not accurately 
reflect the current burden of HCV in Montana.  
 “I would say that the number of Hep C cases is much higher than the information 
 reports. (Every IV drug user should be tested no matter what).” 
 
 “The numbers of cases locally and regionally are low balled.” 
 
 “Higher percentage of people have Hep C.” 
 
 “I believe that in all of Montana the chart we were provided with is bullshit. I am 
 positive that there is more people positive in this state for Hepatitis C.” 
 
 “I would change the amount of how many people have it from 2010 to 2012. I have 
 come across more people with Hep C then people with a STD. I would change the 
 number of people with Hep C.” 
 
Theme 3: Appreciation of the report 
 
The final theme that emerged from the report was appreciation for being able to read the report 
and learn from it. Respondents reported that this report enhanced their previous knowledge of 
HCV.  
 “I didn’t know razors or hygiene can spread [HCV] too. There was a lot of information 
 about it [that] I did not know.” 
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 “I’m glad I’ve been able to take this, because I’ve learned more about my HCV.” 
 
 “I can’t think of any other info that would be useful in this packet. It was also 
 informational to me.” 
 
Secondary Data 
Epidemiological Data 
 
The epidemiological data was provided to the researchers by the Epidemiologist in the 
HIV/STD/HCV Prevention Section of the MTDPHHS. This information does not represent the 
definitive number of HCV cases in Montana and should be used and interpreted with caution. 
Below are some of the factors that have affected the reporting and recording of HCV cases over 
the years. This list does not include all factors that may affect HCV reporting in Montana. 
• Only cases reported since 2010 have been included. Since 2010, there has been more 
rigorous collection of HCV case data into the Montana Infectious Disease Information 
System (MIDIS). 
 
• Progressively greater number of cases does not necessarily indicate more incidence of 
HCV. The characteristics of HCV allow for persons to be infected many years before 
they are diagnosed. Cases finally diagnosed and/or reported in 2012 may have been 
infected several years earlier. Moreover, reported cases may have been infected years 
earlier, resolved their infection, but now have an antibody tests that confirm their past 
infection.  
 
• Changing testing recommendations may have increased the number of persons being 
tested for HCV. 
 
• The counts below include HCV cases that have confirmed, probable, suspect, and 
unknown (meaning unsure of acute or chronic) case status. 
 
• The CDC case definition for HCV has undergone several changes in recent years, which 
has affected the number of cases counted. 
 
• The data provided are an estimate of the burden of HCV in Montana.  
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Table 6 – Total Reported Hepatitis C Virus Cases— Montana, 2010–2012 
 
 Chronic HCV cases Acute HCV cases Total HCV cases 
Total 3827 22 3849 
 
Table 7 – Reported Hepatitis C Virus Cases by Year — Montana, 2010–2012 
 
Year Chronic HCV cases Acute HCV cases Total HCV cases Case Rate Per 
1,000 People 
2010 925 4 929 .938* 
2011 1345 9 1354 ** 
2012 1557 9 1566 1.56*** 
* 2010 Montana population was 989,415 (U.S. Census Bureau, 2013). 
** No total population estimates for 2011 were reported by the U.S. Census Bureau. 
*** 2012 Montana Population was 1,005,141 (U.S. Census Bureau, 2013). 
 
Table 8 – Reported Hepatitis C Virus Cases by Sex and Year — Montana, 2010–2012 
 
 Year 
Sex 2010 2011 2012 2010–2012 
Male 496 721 883 2100 
Female 433 633 682 1748 
Unknown 0 0 1 1 
Total 929 1354 1566 3849 
 
 
Table 9 – Reported Hepatitis C Virus Cases by Age Category and Year — Montana, 2010–
2012 
 
 Year 
Age (years) 2010 2011 2012 2010–2012 
<15 2 9 11 22 
15–19 17 27 28 72 
20–24 74 102 129 305 
25–29 83 146 160 389 
30–34 84 150 155 389 
35–39 80 121 128 329 
40–44 83 129 125 337 
45–49 148 183 179 510 
50–54 145 185 235 565 
55–59 126 184 233 543 
≥60  85 116 182 383 
Unknown 2 2 1 5 
Total 929 1354 1566 3849 
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Table 10 - Reported Hepatitis C Virus Cases by County and Year — Montana, 2010–2012 
 
 Year 
County 2010 2011 2012 2010–2012 
Beaverhead 10 3 11 24 
Big Horn/Crow 20 19 23 62 
Blaine/Ft. 
Belknap 
15 15 13 43 
Broadwater 3 4 6 13 
Carbon 2 8 11 21 
Cascade 80 102 114 296 
Chouteau 1 0 4 5 
Custer 9 7 7 23 
Daniels 0 1 1 2 
Dawson 9 6 5 20 
Deer Lodge 3 15 12 30 
Fallon 0 1 0 1 
Fergus 8 14 10 32 
Flathead 54 66 106 226 
Gallatin 64 69 86 219 
Garfield 0 0 1 1 
Glacier/Blackfeet 57 81 87 194 
Golden Valley 0 1 0 1 
Granite 0 0 1 1 
Hill/Rocky Boy 12 24 39 75 
Jefferson 3 8 5 16 
Judith Basin 0 0 1 1 
Lake/CSKT 32 47 33 112 
Lewis & Clark 60 61 83 204 
Liberty 1 0 0 1 
Lincoln 19 32 29 80 
Madison 4 6 4 14 
McCone 0 1 2 3 
Meagher 0 0 3 3 
Mineral 1 3 4 8 
Missoula 104 183 178 465 
MT State Prison 0 1 61 62 
Musselshell 5 6 5 16 
Park 12 15 23 50 
Phillips 0 1 5 6 
Pondera 2 0 4 6 
Powder River 0 5 2 7 
Powell 15 55 15 85 
Prairie 0 1 1 2 
Ravalli 25 17 29 71 
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Richland 4 4 4 12 
Roosevelt/Ft. 
Peck 
63 90 105 258 
Rosebud/Northern 
Cheyenne 
15 22 15 52 
Sanders 4 9 15 28 
Sheridan 0 3 0 3 
Silver Bow 36 90 92 218 
Stillwater 2 5 10 17 
Sweet Grass 2 0 1 3 
Teton 3 0 6 9 
Toole 3 14 7 24 
Valley 4 5 7 16 
Wheatland 0 1 1 2 
Yellowstone 163 233 279 675 
Total 929 1354 1566 3849 
 
Table 11 – Percent HCV Cases per County 
County Number of Cases (2012) Population (2012)* Case Rate per 
1,000 People 
Lewis and Clark 83 64,876 1.23 
Gallatin 86 92,614 .929 
Flathead 106 91,633 1.16 
Roosevelt/Ft.Peck 105 10,927 9.6 
Cascade 114 81,723 1.39 
Missoula 178 110,977 1.60 
Yellowstone 279 151,882 1.84 
* 2012 U.S. Census Bureau data from various Montana counties (U.S. Census Bureau, 2013). 
	  
	  
84	  
 
  CHAPTER 5 
 
Assessment Methods 
	  
This study utilized a descriptive case study design to examine the impact of HCV in Montana. 
Four data collection methods were used. First, a comprehensive review of the literature was 
completed. Second, eight interview sessions were conducted with key informants throughout the 
state. A total of ten individuals participated in the interviews. Third, epidemiological data 
solicited from the state public health department was used to describe the burden of HCV in 
Montana. Finally, 45 people living with HCV provided written feedback in response to their 
review of a summary report prepared by the researchers that included a synthesis of the literature 
review and key informant interviews. 
Demographics 
 
The ten key informant interview participants represented three of Montana’s five health planning 
regions (see Appendix G). Seven females and three males participated. All but three of the key 
informants worked in a medical or public health setting and had expertise in the prevention 
and/or treatment of HCV. The remaining three key informants were established HIV and HCV 
outreach workers. 
 
Overall, the demographic characteristics of the individuals living with HCV who agreed to read 
and complete the summary report varied broadly. There were, however, similarities among those 
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individuals. The vast majority were males between the ages of 25-54, who make less than 20,000 
dollars annually and live in Regions 3 and 4 of Montana.  
 
Discussion 
	  
The following discussion represents a synthesis of data collected, both qualitatively through 
interviews and summary report comments and quantitatively through the epidemiological data 
and demographic form included in the summary report. Despite the fact that information about 
HCV cases in Montana is incomplete and that there are several limitations to the data, it is 
known that roughly 4,000 HCV positive tests were reported to the MTDPHHS between 2010 and 
2012. The regions that showed the greatest case numbers were also, for the most part, 
represented by the majority of the HCV positive participant sample. The researchers explored 
factors influencing HCV transmission; the physical, social, and psychological effects of not only 
having HCV, but also going through HCV treatment; the barriers to prevention and treatment; 
current available resources to those presently infected with HCV and ways to improve HCV 
prevention and treatment in Montana. 
 
Key Factors Contributing to HCV Infection 
Poverty 
	  
Throughout the literature, key informant interviews and summary reports, poverty emerged as a 
prominent theme. In this study, the relationship between poverty and HCV infection was viewed 
from two perspectives. The majority of key informants reported that poverty plays a role in HCV 
infection because people living in poverty tend to use drugs to cope with the many issues 
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associated with poverty. The practice of injecting drugs and sharing needles/syringes is 
particularly dangerous because it is the most efficient mode of HCV transmission due to the fact 
that HCV can live in a syringe for up to 63 days (HCV Advocate, 2010). Although this issue was 
not directly addressed by the key informants, the literature provides support for the idea that 
individuals living in poverty who inject drugs tend to share needles/syringes more often than 
their wealthier counterparts. In fact, in 2009, a study that looked at HIV infection and HIV 
associated behaviors among injecting drug users, Wejnert et al. found that a higher percentage of 
those living at or below the federal poverty level (35%) shared syringes than those above the 
poverty level (27%) (CDC, 2009b). Moreover, The WHO reported that the global incidence of 
HCV amongst PWID is higher in low- and middle-income countries than in high-income 
countries (WHO, 2012a).   
 
On the other hand, despite the current literature and key informants’ assertion that people living 
in poverty are more likely to be infected with HCV because their poverty leads to injection drug 
use, several HCV positive participants disagreed. They believed that poverty and HCV infection 
do not have a direct relationship. One participant summed up his belief by saying, “Drug users 
don’t use drugs because they are poor. People who value work don’t get high. To the extent that 
HCV is transmitted due to drug use, poverty is the result and not the cause.” Another participant 
noted that HCV does not discriminate and can therefore affect everyone equally.  
 
Explaining the discrepancy in findings is not easy. Most likely there is truth in both assertions.  
As the literature states, individuals who are living in poverty are more likely to share needles and 
therefore become infected with HCV. It is also possible, as several HCV positive individuals 
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indicated, that the abuse of drugs can lead a person, who would otherwise be gainfully employed, 
into a life of poverty. The question seems to be, what came first, the drug abuse resulting in 
infection with HCV, leading to a life of poverty, or a life of poverty leading to drug abuse and 
the resulting infection with HCV. 
Lack of access to clean needles 
	  
According to the literature, key informants and HCV positive participants, the lack of access to 
clean needles/syringes is a major contributor to HCV transmission among PWID. In resource 
rich countries, such as the United States, injection drug use is the single most important risk 
factor for acquiring HCV (Iversen, Wand, Gonnermann & Maher, 2010). In fact, the CDC 
estimates that within five years of beginning drug use, between 50-80% of people who inject 
drugs (PWID) will become infected with HCV.   
 
Many studies have indicated that Syringe Exchange Programs (SEPs) reduce risk behavior and 
offer essential care and services to intravenous drug users (Aidsunited.org, 2011). In 2009, 
President Barack Obama removed the nationwide ban on states’ use of federal funds for Syringe 
Exchange Programs (SEPs). Despite the long held support from the Centers for Disease Control 
and Prevention (CDC), the National Institutes of Health (NIH), and the majority of the medical 
and scientific community, the ban was restored in 2012 (Khan, 2012). Clearly, SEPs remain 
politically targeted, not only at the federal level, but also at the state level. Under Montana’s 
Drug Possession Law,  
 “It is unlawful for a person to use or to possess with intent to use drug paraphernalia to…inject,  ingest, 
 inhale, or otherwise introduce into the human body a dangerous drug. A person who violates this section is 
 guilty of a misdemeanor and upon conviction shall be imprisoned in the county jail for not more than six 
 months, fined an amount of not more than $500, or both”  (Montana Code Ann. 45-10-103).  
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Under this law, a used needle or syringe would be evidence of a past crime making it very 
difficult to establish a SEP. Consequently, there are currently only two SEPs in the state; one 
program is located in Fort Peck and the other is in Missoula (Amfar, 2012).   
 
There was broad consensus in the literature and among key informants and HCV positive 
participants that the lack of access to clean needles and syringes leads to greater HCV infections 
among PWID. HCV positive participants believed that people are going to inject drugs 
regardless of education and the availability of a clean needle because once a person is an addict, 
he or she will do anything to “get his/her fix.” As one respondent stated, “In practice, restricting 
the supply of syringes rarely reduces drug use nor does it encourage an IV user to use the drugs 
in another way. The choice for an IV drug user is only clean vs. dirty.” Although needle/syringe 
exchange programs are illegal in Montana, key informants and HCV positive participants felt 
strongly that that clean needles need to be an option for PWID, and that despite common beliefs, 
the availability of clean needles does not lead to increased drug use.  
 
Lack of public education and awareness 
	  
Lack of public education about HCV and therefore ignorance of the ways it is transmitted was 
also found to be an environmental contributor to infection with HCV. Most key informants 
mentioned that the public is not knowledgeable because there is a lack of education in the 
schools about HCV and how it is transmitted. While HIV prevention has been taught in Montana 
public schools for decades, students are not taught about how to prevent infection with HCV. 
Most key informants stated that HCV education needs to start in middle school because middle 
school is when many kids start to experiment with drugs and other risky behaviors. One HCV 
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positive participant indicated that he started injecting drugs when he was 14; he feels that kids 
should learn about HCV in school. Another HCV positive participant stated, “Education and 
awareness [are] critical to fight HCV. Knowledge of prevention, contraction, and the spread of 
the disease among youth is vital I think.” 
 
Moreover, there is a lack of knowledge about HCV among people who use injection drugs 
(PWID). Lack of knowledge about HCV has led to misconceptions about the virus and how it is 
transmitted. As one HCV positive participant stated, “Remember, you can get it from a toilet 
seat!” This was just one example of a few misconceptions about HCV transmission from the 
HCV positive participants. Most key informants stated that many PWID don’t know that HCV 
can be transmitted through the works associated with the injection drugs, therefore, it is 
important to include teaching harm reduction strategies to individuals who are currently using 
injection drugs.  
 
Key Issues for People Infected with HCV 
 
Treatment difficulty 
	  
There was an overwhelming consensus among the literature, key informants and HCV positive 
participants regarding the difficulty of treatment. It is not only difficult to find a physician who 
offers the treatment, but also, difficult to pay for treatment. As confirmed by a key informant 
who treats HCV positive people, there are currently only four facilities in Montana that provide 
HCV treatment.  In a state as vast as Montana, unless a person infected with HCV lives close to 
one of those treatment centers, finding and paying for transportation to medical appointments can 
be very difficult.  
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To make matters worse, HCV treatment can have adverse side effects on patients, such as 
treatment induced-depression (Sockalingam, 2011). Depression is the most common 
psychological side effect of Pegylated Interferon (Peg-IFN), which is one of the three drugs in an 
HCV treatment regimen. As one key informant who treats HCV positive people stated, 
“Interferon has a black box warning that it can cause depression in 25% of patients who are 
treated who have never been depressed. And, certainly if you have underlying depression, it can 
exacerbate that.”  
 
The majority of key informants also agreed that HCV treatment can cause tremendous negative, 
psychological side effects. In fact, a few key informants stated that the side effects of HCV 
treatment are so terrible that it may not even be worthwhile for some to go through treatment. 
One HCV positive participant summed up his/her treatment experience: “I did become 
depressed, I also wasn’t able to work…couldn’t think or talk right, it was a living hell.” The 
majority of HCV positive participants reported these issues with HCV treatment. In fact, a few 
mentioned they had to stop treatment because their side effects were so tremendous.  
 
It is, however, important to note that many of the current issues surrounding treatment for HCV 
infection may decrease in importance in the next several years. The interferon-free Direct 
Actions Antiviral (DAA) treatments that are currently undergoing clinical trial testing, have not 
only produced fewer side-effects and complications than interferon, but also were found to have 
a 90% cure rate (Martin et al., 2013). Moreover, treatment time has been found to be roughly 25-
33% shorter; interferon treatment is 36-48 weeks, while DAA treatments only require 12 weeks 
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(Martin et al., 2013). Although interferon is still currently being used to treat people living with 
HCV, it is clear that HCV treatment will be vastly improved in the next few years.  
 
Stigma 
	  
The relationship between stigma and HCV was pervasive throughout the literature, key 
informant interviews and summary reports. Infectious diseases carry enormous societal stigma; 
therefore, by association, a person infected with HCV has the potential to be highly stigmatized 
(Evon et al., 2012). Add the stigma of injection drug use to the stigma of the infectious disease 
and it is not surprising that key informants and HCV positive individuals indicated that the 
overwhelming social and emotional effects of both HCV diagnosis and treatment are feelings of 
isolation, hopelessness and judgment by others. 
 
The stigma is not only found socially, but also it can be found among health care providers. Most 
key informants mentioned how physicians treat patients with HCV poorly because of the “IV 
drug user” stigma that HCV diagnosis carries. Key informants also indicated that physicians tend 
to be more judgmental about how the patient contracted HCV based upon physical appearance. 
According to one key informant, if the patient has tattoos, the physician has likely already 
decided how the virus was contracted. One HCV positive participant summed up his/her feelings 
about stigma from the medical professionals: “People need to have access to proper food, 
medical, and dental without having to be afraid of being treated like they are nothing but 
garbage. We are all people with feelings, even if we are addicts and poor!”  
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Recommendations for Improvement 
Prevention 
	  
Key informants and HCV positive participants agreed that the best ways to improve HCV 
prevention in the state of Montana are as follows: increase the media attention and therefore 
awareness of HCV, and to increase education about HCV. With optimally targeted media 
campaigns, HCV prevention could be highly successful. Media outlets that key informants 
mentioned include: social media platforms such as Facebook and Twitter, public campaigns and 
public service announcements. Including personal stories about people living with HCV is 
important. As one key informant mentioned, the public is always more affected by media that 
includes personal stories, rather than those that do not. With a greater use of media, there is 
potential that fewer people would feel the way this HCV positive participant felt: “You never 
hear about HCV like you do HIV and other STDs.” 
 
Greater education also was mentioned by the majority of study participants as the best way to 
improve HCV prevention. As one HCV positive participant stated, “Education is critical to fight 
HCV; knowledge of prevention, contraction and the spread of the disease among youth is vital, I 
think.” As key informants mentioned, education also is the best way to de-stigmatize the virus. 
By educating not only children in school, but also adults about HCV and its transmission routes, 
much of the stigma can be removed.  
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Treatment 
	  
Key informants and HCV positive participants overwhelmingly agreed that the two best ways to 
improve treatment are to decrease the cost and increase the accessibility in Montana. As 
mentioned by almost all participants in the study, HCV treatment is too expensive and this 
becomes a barrier to treatment for many. Although a key informant mentioned that there are 
ways for those who can’t afford treatment to get it, the majority of key informants reported that 
most people with HCV do not qualify for those options and therefore cannot afford treatment. 
With decreased treatment costs, more people would be able to receive treatment and possibly 
attain a Sustained Virologic Respone (SVR, meaning the virus is undetectable in a person’s 
system for six months or more). This would further reduce the spread of the virus due to fewer 
people living with HCV and the decreased viral loads (the amount of detectable virus in a 
person’s system). 
 
Both key informants and HCV positive participants indicated that HCV treatment is not easily 
accessible in Montana. As a key informant mentioned, there are only four facilities in Montana 
that treat HCV. One HCV positive participant reported that he had to drive 2.5 hours just to get 
his HCV treatment:  
“My doctor did a terrible job of attempting to minimize the number of trips I had to make for 
office visits. He would insist on an appointment, then a blood test and then a follow up to talk 
about the blood test results. He should have ordered blood tests 2 weeks before the visit and 
required only 1 trip to the office rather than 2. It took 5 hours round trip to see him. Doubling up 
the visit adds up over the course of 48 weeks of treatment.” 
 
Better access to treatment would allow more people living with HCV decrease their viral load 
and potentially achieve an SVR. Furthermore, treatment can now be considered as a prevention 
effort due to the reduction in viral load.  
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Key informants mentioned Project ECHO as a means of administering HCV treatment through 
Nurse Practitioners and Physician Assistants. By having these practitioners administer HCV 
treatment, rather than a physician, this would allow for greater access to HCV treatment, 
especially in rural parts of Montana where physicians are very limited.  
 
Despite the need for more affordable treatment and greater access to treatment in the state of 
Montana, lack of funding is likely to make these recommendations difficult to implement. 
Currently, greater funding is not available because state and federal funding for HCV is not a 
priority. A more realistic recommendation for improving affordability and access to treatment 
would be to increase the public’s awareness of the existence of low cost HCV testing and 
treatment available through three of Montana’s Federally Qualified Health Centers. Increased 
awareness about testing and treatment availability could lessen the burden of HCV in Montana 
through greater identification and treatment of existing cases.  
 
Limitations 
	  
A number of limitations exist in this research. Specifically, the information collected in this 
study was limited to the experiences of key informants and people living with HCV who 
completed the summary report. Key informants were selected via convenience sampling. 
Furthermore, key informants who sent out the summary reports did not randomly select HCV 
positive participants, rather, participants were chosen by the key informant based upon their 
likelihood and interest in completing the report. Therefore, people living with HCV, who 
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reviewed the summary report, may not have been representative of all the individuals in Montana 
living with HCV.  
 
It is also important to note that the majority of HCV positive participants lived in Montana’s 
planning regions 3 and 4, and reported incomes below $20,000 per year. The low socio-
economic status of study participants may, in part, explain the emphasis on poverty and the 
difficulty in accessing treatment. Moreover, the epidemiological data only reflects individuals 
who have been tested for HCV, and whose test results have been reported to the state and 
variation in reporting by health-care providers, laboratories, and health departments vary greatly 
(CDC, 2013). Therefore, more individuals are infected with HCV than are represented by the 
data. Finally, a potential bias in this study was that the vast majority of key informants who were 
interviewed work in HCV prevention, rather than treatment. It is possible that more prevention 
themes rather than treatment themes emerged due to the nature of the key informant sample.  
 
 
Conclusions 
 
Although information about HCV cases is incomplete and there are multiple limitations related 
to the collection of information related to incidence and prevalence, it is known that nearly 4,000 
HCV positive tests were reported to MTDPHHS between 2010 and 2012. Little is known, 
however, about the people who test positive for HCV and are living in Montana. Therefore, the 
purpose of this study was to collect available information about the distribution of HCV in 
Montana and to explore its impact on people who are infected with the virus. Participants 
recruited for this study included forty-five people living with HCV in Montana who reviewed 
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and completed the summary report and ten key informants who participated in interviews. While 
participants in this study may not be representative of all people living with HCV in Montana, 
information gathered from them provides insight into several key issues.  
 
Poverty was one of the most salient issues that arose from the data. Poverty was related to a 
higher rate of infection with HCV. The nature of the relationship between poverty, injection drug 
use and HCV infection, however, was unclear. While the key informants believed that poverty 
drove individuals to use injection drugs, the HCV positive participants believed that drug use 
drove individuals into poverty. What was apparent in this study was that the majority of HCV 
positive participants were living close to or below the poverty level.  
 
Another major issue was the lack of access to clean needles. Montanans who participated in this 
study strongly voiced the opinion that it is time to consider the creation of sanctioned syringe 
exchange programs in the state. Along with access to clean needles, access to treatment also was 
important to study participants. In a state that ranks fourth in size and 44th in population, people 
living with HCV often find it difficult to travel to one of the four treatment centers in Montana.  
 
Finally, better education about HCV in public schools and through various media channels were 
strongly encouraged. Education would not only serve to provide information that could prevent 
the transmission of HCV, but also could serve to decrease the stigma and shame experienced by 
individuals who are infected. For decades the HCV epidemic has been a nearly invisible one. 
The time has come for the federal government and for the state of Montana to shed some light on 
this preventable illness. Only when we have an understanding of the distribution of the infection 
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and the barriers to prevention and treatment can we help the people of our state who are living 
with HCV. 
	  
	  
98	  
 
WORKS CITED 
 
Barriero, P., Vispo, E., Labarga, P. and Soriano, V. (2012). Mangement and treatment of chronic 
 hepatitis C in HIV patients. Semin Liver Disease, 32(2), 138-146 
Centers for Disease Control and Prevention [CDC] (2012a). Hepatitis C, Chronic: 2010 Case 
 Definition, Retrieved August 21, 2012 from:
 http://www.cdc.gov/osels/ph_surveillance/nndss/casedef/hepatitisc2010.htm 
Centers for Disease Control and Prevention [CDC] (2012b). Hepatitis C: Expansion of Testing 
 Recommendations, 2012. Retrieved September 1, 2012 from:
 http://www.cdc.gov/nchhstp/newsroom/docs/2012/HCV-TestingRecsFactSheet_508.pdf 
Centers for Disease Control and Prevention [CDC] (2010a). Hepatitis C: Information About 
 Testing, Retrieved September 1, 2012 from: 
 http://www.cdc.gov/hepatitis/HCV/PDFs/HepCTesting-Diagnosis.pdf 
Centers for Disease Control and Prevention [CDC] (2011). Hepatitis C Information for Health   
 Professionals. Retrieved August 21, 2012 from: 
 http://www.cdc.gov/hepatitis/HCV/index.htm 
Centers for Disease Control and Prevention [CDC] (2009a). HIV-associated behaviors among 
 injecting-drug users-23 cities. Morbidity and Mortality Weekly Report (MMWR), 61(08), 
 133-138. 
Centers for Disease Control and Prevention [CDC] (2009b). HIV infection and HIV-associated 
 behaviors among injecting-drug users-20 cities, United States, May 2005-February 2006. 
 Morbidity and  Mortality Weekly Report (MMWR), 58(13), 329-332. 
Centers for Disease Control and Prevention [CDC] (2010c). Notes from the Field: Hepatitis C 
 Virus Infections Among Young Adults-Rural Wisconsin, 2010. Morbidity and Mortality 
 Weekly Report (MMWR), 61(19), 358-358. 
Centers for Disease Control and Prevention [CDC] (2010b). Syringe Exchange Programs: United 
 States, 2008. Morbidity and Mortality Weekly Report (MMWR), 59(45), 1488-1491. 
Centers for Disease Control and Prevention [CDC] (2002). Viral Hepatitis and Injection Drug 
 Users. Retrieved September 1, 2012 from: 
 http://www.cdc.gov/idu/hepatitis/viral_hep_drug_use.pdf 
Centers for Disease Control and Prevention [CDC] (2013). Vital signs: Evaluation of hepatitis C 
 virus infection testing and reporting-8 U.S. site, 2005-2011. Morbidity and Mortality 
 Weekly Report (MMWR), 62 (18), 357-361. 
Choi, P. (2013). MTDPHHS HIV/STD/HCV Prevention Section. HCV Epidemiological Data. 
	  
	  
99	  
Council of State and Territorial Epidemiologists [CSTE] (2012). Hepatitis C, Acute: 2012 Case 
 Definition. CSTE Position Statement Number: 11-ID-05. Retrieved September 5, 2012. 
Denniston, M.M., Klevens, R.M., McQuillan, G.M., and Jiles, R.B. (2012). Awareness of 
 Infection, Knowledge of Hepatitis C, and Medical Follow-Up Among Individuals Testing 
 Positive for Hepatitis C: National Health and Nutrition Examination Survey 2001-2008. 
 Journal of Hepatology 55 (6), 1652-1661. 
Doyle, J.S., Aspinall, E., Liew, D., & Thompson, A.J. (2012). Current and emerging antiviral 
 treatments for hepatitis C infection. British Journal of Clinical Pharmacology. Advance 
 online publication. doi: 10.1111/j.1365-2125.2012.04419. 
Evon, D.M., Golin, C.E., Fried, M.W., & Keefe, F.J. (2012). Chronic Hepatitis C and Antiviral 
 Treatment Regimens: Where Can Psychology Contribute? Journal of Consulting and 
 Clinical Psychology. Advance online publication. doi: 10.1037/a0029030 
Franciscus, A. (2010). HCV Advocate: How long does HCV live on surfaces and in syringes? 
 Retrieved March 15, 2013 from: 
 http://www.hcvadvocate.org/hepatitis/factsheets_pdf/How%20long_10.pdf 
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009). Diagnosis, management, and 
 treatment of hepatitis C: An update. Hepatology, 49, 1335–1374. doi:10.1002/hep.22759 
 
Gilmore, G.D. & Campbell, M.D. (2005). Needs and Capacity Assessment Strategies for Health 
 Education and Health Promotion. Sudbery, MA: Jones and Bartlett. 
 
Goffman, E. (1963). Stigma: Notes on the management of spoiled identity. Engelwood Cliffs, NJ: 
 Prentice Hall. 
 
Gordis, L., (2004).  Epidemiology, (3rd ed.).  Elsevier, Inc:  Philadelphia, PA.   
Iverson, J., Wand, H., Gonnermann, A., and Maher, L. (2010). Gender differences in hepatitis C 
 antibody prevalence and risk behaviours amongst people who inject drugs in Australia 
 1998-2008. International Journal of Drug Policy, 21, 471-476. 
Khan, A. (2012). Despite show of support, federal funding ban on needle exchange unlikely to 
 be lifted anytime soon. Public Broadcasting Service. Retrieved from 
 http://www.pbs.org/wgbh/pages/frontline/social-issues/endgame-aids-in-black-
 america/despite-show-of-support-federal-funding-ban-on-needle-exchange-unlikely-to-
 be-lifted-anytime-soon/ 
Korthuis, P.T., Feaster, D.J., Gomez, Z.L., Das, M., Tross, S., Wiest, K., Douaihy, A., Mandler, 
 R.N., Sorenson, J.L., Colfax, G., McCarty, D., Cohen, S.E., Pen, P.E., Lape, D., & 
 Metsch, L.R. (2012). Injection behaviors among injection drug users in teatment: The 
 role of hepatitis C awareness. Journal of Addictive Behaviors, 37, 552-555. 
Lavanchy, D. (2011). Evolving Epidemiology of Hepatitis C Virus. Clinical Microbiology and 
 Infection, 17 (2), 107-114. 
	  
	  
100	  
Leutscher, P.D., Lagging M., Buhl, M.R., Pedersen, C., Norkrans, G., Langeland, N., Mørch, K., 
 Färkkilä, M., Hjerrild, S., Hellstrand, K., and Bech, P. (2010). Evaluation of depression 
 as a risk factor for treatment failure in chronic hepatitis C. Journal of Hepatology, 52 (2), 
 430-435. 
Martin,N.K. Vickerman, P., Grebely,J.,Hellard,M, Hutchinson, S.J., Lima, V.D., Foster, G., 
 Dillon, D.J., Goldberg, Dore, G.J., & Hickman, M. (2013). HCV treatment for prevention 
 among people who inject drugs: Modeling treatment scale-up in the age of direct-acting 
 antivirals. Hepatology, DOI: 10.1002/hep.26431 
Merriam Webster Dictionary (2012). Antibody. Retrieved September 1, 2012 from: 
 http://www.merriam-webster.com/dictionary/antibody 
Merriam Webster Dictionary (2012). Antigen. Retrieved September 1, 2012 from: 
 http://www.merriam-webster.com/dictionary/antigen 
Morasco, B.J., Rifai, M.A., Loftis, J.M, Indest, D.W., Moles, J.K., and Hauser, P. (2007). A 
 randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients 
 with hepatitis C. Journal of Affective Disorders. 103, 83-90. 
North American Syringe Exchange Network [NASEN] (2012). Montana Syringe Exchange 
 Program Database. Retrieved October 5, 2012 from: 
 http://www.nasen.org/programs/us/mt/ 
Naggie, S. and Sulkowski, M.S. (2012). Management of Patients Coinfected With HCV and 
 HIV: A Close Look at the Role for Direct-Acting Antivirals. Gastroenterology, 142, 
 1324-1334. 
 
National Digestive Diseases Information Clearinghouse [NDDIC] (2012). Cirrhosis. Retrieved 
 November 10, 2012 from: 
 http://digestive.niddk.nih.gov/ddiseases/pubs/cirrhosis/#symptoms 
 
NIH Consensus Development Program [NCDP] (2002). Management of Hepatitis C: 2002. 
 Retrieved September 7, 2012 from: 
 http://consensus.nih.gov/2002/2002hepatitisc2002116html.htm 
Norden, L., Saxon, L., Kaberg, M., Kall, K., Franck, J., & Lidman, C. (2009). Knowledge of 
 status and assessment of personal health consequences with hepatitis C are not enough to 
 change risk behaviors among injecting drug users in Stockholm County, Sweden. 
 Scandinavian Journal of Infectious Diseases, 41(10), 727-734. 
QSR International (2011). NVivo 9: Getting Started. Retreived October 12, 2012 from: 
 http://download.qsrinternational.com/Document/NVivo9/NVivo9-Getting-Started-
 Guide.pdf 
Rhodes, T., Singer, M., Bourgois, P., Friedman, S.R. & Strathdee, S.A. (2005). The social 
 structural production of HIV risk among injecting drug users. Social Science and 
 Medicine, 61 (5), 1026-1044.  
	  
	  
101	  
Ribeiro, R.M., Layden-Almer, J., Powers, K.A., Layden, T.J., and Perelson, A.S. (2003). 
 Dynamics of Alanine Aminotransferase During Hepatitis C Virus Treatment. Journal of 
 Hepatology, (38) 2, 509-517.  
Rimer, B. & Glanz, K. (2005). Theory at a Glance: A guide for health promotion practice (2nd 
 ed.). U.S. Department of Health and Human Services: National Institutes of Health.  
Rossaro, L. (2003). Hepatitis C and Telemedicine Technology: Closing the Gap in Access to 
 Care. HCV Advocate: Medical Writers’ Circle. Retrieved from: 
 http://www.hcvadvocate.org/hcsp/articles/ROSSARO.html 
Sacks-Davis, R., Horyniak, D., Grebely, J., and Hellard, M. (2012). Behavioural interventions 
 for preventing hepatitis C infection in people who inject drugs: A global systematic 
 review. International Journal of Drug Policy, 23, 176-184. 
 
Salkind, N. (2006). Exploring research (6th ed.). Pearson Education, Inc.:Upper Saddle  
River, New Jersey. 
 
Scalori, A., Pozzi, M., Bellia, V., Apale, P., Santamaria, G., Bordoni, T., Redaelli, A., Avolio, 
 A., Parravicini, P., Piotelli, P., and Roffi, L. (2005). Interferon-induced depression: 
 Prevalence and management. Digestive and Liver Disease, 27, 102-107. 
 
Schaefer, M., Hinzpeter, A., Mohmand, A., Janseen, G., Pich, M., Schwaiger, M., Sarkar, R., 
 Friebe, A., Heinz, A., Kluschke, M., Ziemer, M., Gutsche, J., Weich, V., Halangk, J., & 
 Berg, T. (2007). Hepatitis C Treatment in “Difficult-to-Treat” Psychiatric Patients with 
 Pegylated Interferon-Alpha and Ribavirin: Response and Psychiatric Side Effects. 
 Journal of Hepatology, 46 (4), 991-999. 
Sherman, M., Shafran, S., Burak, K., Doucette, K., Wong, W., Girgrah , N., Yoshida, E., Renner, 
 E., Wong, P., and Deschenes, M. (2007). Management of chronic hepatitis C: Consensus 
 guidelines. Canadian Journal of Gastroenterology, 21: 25C-34C. 
 
Smith, B.D., Morgan, R.L., Beckett, G.A., Falck-Ytter, Y., Holtzman, D., Teo, C.G., Jewett, 
 A.,Baack, B., Rein, D.B., Patel, N. Alter, M., Yartel, A., & Ward, J.W. (2012). 
 Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among 
 Persons Born During 1945-1965. Morbidity and Mortality Weekly Recommendations and 
 Reports, 61 (4), 1-18. 
Sockalingam, S., Links, P.S., and Abbey, S.E. (2011). Suicide risk in hepatitis C and during 
 interferon-alpha therapy:a review and clinical update. Journal of Viral Hepatitis, (18), 
 153-160.  
Sulkowski, M.S, Moore, R.D, Mehta, S.H., Chaisson, R.E., and Thomas, D.L. (2002). Hepatitis 
 C and progression of HIV disease. JAMA, 288, 199-206. 
 
Swan, T. (2006). U.S. Department of Health and Human Services [USDHHS]. Care and 
treatment for hepatitis C and HIV coinfection: Expanding access through Ryan White 
	  
	  
102	  
CARE Act. Retrieved October 5, 2012 from: 
http://www.cdc.gov/hepatitis/HCV/PDFs/HRSA-HIV-HCV_2006.pdf 
Udina, N., Castellvi, P., Moreno Espana, J., Navines, R., Valdes, M., Forns, X., Langohr, K., 
 Sola, R., Vieta, E., and Martin-Santos, R. (2012). Interferon-induced depression in 
 chronic hepatitis C: a systematic review and meta-analysis. Journal of Clinical 
 Psychiatry, 73(8), 1128-1138. 
Ulin, P., Robinson, E., & Tolley, E. (2005). Qualitative methods in public health: a field guide 
for applied research. San Francisco, CA: Jossey Bass. 
United States Department of Commerce (2013). United States Census Bureau: State and County 
QuickFacts. Retrieved May 1, 2013 from: 
http://quickfacts.census.gov/qfd/states/30000.html 
United States Department of Veterans Affairs [USDVA] (2012). Hepatitis C RIBA: 
 Understanding Lab Tests. Retrieved September 1, 2012 from: 
 http://www.hepatitis.va.gov/patient/diagnosis/labtests-hepatitisC-RIBA.asp 
United States Department of Veterans Affairs [USDVA] (2011). Hepatitis C Medications: A 
 Review and Update for Patients. Retrieved August 28, 2012 from: 
 http://www.hepatitis.va.gov/products/patient/treatment-update.asp 
World Health Organization [WHO] (2002). Hepatitis C. Retrieved August 31, 2012 from: 
 http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index.html  
World Health Organization [WHO] (2012a). Guidance on Prevention of Viral Hepatitis B and C 
 Among People Who Inject Drugs. Retrieved October 1, 2012 from: 
 http://apps.who.int/iris/bitstream/10665/75357/1/9789241504041_eng.pdf 
World Health Organization [WHO] (2012b). Hepatitis C: Fact Sheet. Retrieved August 31, 2012 
 from: http://www.who.int/mediacentre/factsheets/fs164/en/index.html 
Wu, Z., Luo, W., Sullivan, S., Rou, K., Lin, P. & Liu, W. (2007). Evaluation of a needle 
 social marketing strategy to control HIV among injecting drug users in China. 
 AIDS, 21(Suppl. 8), S115–S122.  
 
Yin, R.K. (2003). Case Study Research: Design and Methods. Thousand Oaks, CA: Sage 
 Publications. 
Younossi, Z., Kallman, J., and Kincaid, J. (2007) The Effects of HCV Infection and Management 
 on Health-Related Quality of Life. Journal of Hepatology, 45 (3), 806-815. 
 
 
 
	  
	  
103	  
APPENDIX A: KEY INFORMANT INTERVIEW QUESTIONS 
1. Behaviors and environmental factors contributing to HCV infection in Montana: 
a. What behaviors do you believe contribute to infection with HCV in Montana?  
  
b. What environmental factors do you believe contribute to infection with HCV in 
Montana? (i.e. lack of access to syringes, isolation, etc.) 
 
c. What factors do you believe influence the behaviors that you mentioned in Montana? 
 
2. Physical, Social and Psychological Effects of HCV infection: 
a. What do you believe the physical, social and psychological effects of living with HCV 
are in Montana? 
 
b. What do you believe the physical, social and psychological effects of HCV treatment are 
in Montana? 
 
3. Barriers to HCV Prevention and Treatment: 
a. What do you believe are the barriers to preventing and treating HCV infection in 
Montana? 
 
b. How could these barriers reduced or eliminated? 
  
4. Prevention and Treatment services for Those Infected with HCV: 
a. What prevention services are available to people who are infected with HCV in 
Montana? 
 
b. What treatment services are available to people who are infected with HCV in Montana? 
 
5. Suggestions for Improvement of HCV Prevention and Treatment: 
a. What can be done to improve HCV prevention in Montana? 
 
b. What can be done to improve HCV treatment in Montana? 
 
6. Further thoughts: 
a. Do you have any further thoughts relating to individuals living with HCV in Montana? 
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APPENDIX B: KEY INFORMANT INTERVIEW RECRUITMENT SCRIPT 
Verbal Instructions for Recruiting Volunteers for the Interview 
 
Provide each potential volunteer with an explanation of the interview; and a brief 
explanation of the procedures for the interview. 
 
Purpose:   
This study will aim to fill gaps in information about HCV in Montana by providing data 
regarding HCV transmission, factors influencing transmission, epidemiological information, 
information about barriers to prevention and treatment, and current available resources to those 
presently infected with HCV.  The Montana Department of Public Health and Human Services 
(MTDPHHS) and local health departments will use information from this study to help increase 
awareness of how HCV impacts Montana residents.  Information from this study could lead to 
better and more optimally targeted prevention efforts.  
 
Please remind them: 
• The study is completely voluntary and confidential and they may choose not to answer 
any of the questions posed at the interview. 
 
• If they volunteer they will be asked to meet with the researcher who will ask them 
questions about infection with HCV.  
 
• The interview will be audio recorded, but no identifying information will be transcribed 
from the interview and the tapes will be erased at a later date. 
   
• By participating they are helping fight the spread of HCV in Montana.  The information 
gathered by the interview will be used to improve HCV prevention and treatment 
programs in Montana. 
 
If individuals are willing to participate, give them a copy of the interview questions, the 
researcher’s contact information, and ask them if they would like to make the initial 
contact with the researcher or if it is okay for the researcher to contact them to set up a 
time and place for the interview.   
 
Allow a few minutes for potential participants to ask any question or talk it over. 
• Ask them to fill out a card with contact information if they think they are interested and 
turn it back in to you. 
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APPENDIX C: KEY INFORMANT INTERVIEW CONSENT FORM 
 
KEY INFORMANT INTERVIEW PARTICIPANT CONSENT FORM 
 
 
TITLE: Examining the Impact of Hepatitis C in Montana: A Descriptive Case Study 
 
SPONSOR 
The Montana Department of Public Health and Human Services – HIV/STD/HCV Prevention 
Section 
 
STUDY DIRECTOR: 
Dr. Annie Sondag 
The University of Montana    
Department of Health & Human Performance  
Missoula, MT 59812                          
(406) 243-5215 
annie.sondag@mso.umt.edu 
 
SPECIAL INSTRUCTIONS 
The language in this consent form may be new to you.  If you read any words that are not clear to 
you, please ask the person who gave you this form to explain them to you. 
 
PURPOSE: 
This study will aim to fill gaps in information about HCV in Montana by providing data 
regarding HCV transmission, factors influencing transmission, epidemiological information, 
information about barriers to prevention and treatment, and current available resources to those 
presently infected with HCV.  The Montana Department of Public Health and Human Services 
(MTDPHHS) and local health departments will use information from this study to help increase 
awareness of how HCV impacts Montana residents.  Information from this study could lead to 
better and more optimally targeted prevention efforts.  
 
PROCEDURES 
Interview participation for this study is voluntary.  You are asked to read this consent form.  If 
you agree to participate you will be asked to answer a number of questions covering various 
topics concerning HCV in Montana.  The interview will take approximately one hour.  The 
session will be audio recorded and transcribed for accuracy of responses.   
 
RISKS/DISCOMFORTS 
You may feel you do not know the answer or some of the questions may make you feel 
uncomfortable. You are welcome to refrain from answering any question for any reason or to 
discontinue your participation at any time. 
 
BENEFITS 
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Your help with this study will provide valuable information to the Montana Department of 
Public Health and Human Services.  By participating in this study, your answers will help staff 
offer services and develop programs to prevent future spreading of HCV and improve the lives 
of those already infected with HCV.  
 
CONFIDENTIALITY  
All information collected during your interview will be confidential.  Interviewers will avoid 
identifying any of the participants.  Interviewers will not use your name or any other identifying 
information in reports or any other materials related to this study.  Specifically: 
 
o The identities of all interview participants will remain confidential and will not be 
associated with research findings in any way. 
o At the conclusion of the study, any and all data containing information about participants 
will be destroyed. 
 
COMPENSATION FOR INJURY 
The study team believes the risk of taking part in this study is minimal.  However, the following 
liability statement is required in all University of Montana consent forms: 
 
 In the event that you are injured as a result of this research you should individually 
seek appropriate medical treatment.  If the injury is caused by the negligence of the 
University or any of its employees, you may be entitled to reimbursement by the 
department of Administration under the authority of MCA, Title 2, Chapter 9.  In 
the event of a claim of such injury, further information may be obtained from the 
University’s claims Representative or University Legal Counsel.   
 
VOLUNTEER PARTICPATION/WITHDRAWAL 
Your decision to take part in this research study is entirely voluntary.  You are free to 
NOT answer any question and to discontinue participation at any time.  You also may 
withdraw from this study for any reason.   
 
QUESTIONS 
If you have any questions about the research now or later, you may contact Dr. Annie 
Sondag at (406) 243-5215 or Annie’s Research Assistant, Blair Snyder, at (650) 823-
1786. 
 
If you have any questions about your rights as a research subject you may contact the Chair of 
the Institutional Review Board in the Research Office at The University of Montana – Phone 
(406) 243-6670. 
 
CONSENT 
I have read the above description of this study.  I have been informed of the risks and benefits 
involved, and all of my questions have been answered to my satisfaction.  Furthermore, I have 
been assured that any future questions I may have will be answered by a member of the study 
team.  I voluntarily agree to take part in this study.  I am at least 18 years old.  I understand this 
is my copy of this consent to keep. 
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APPENDIX D: KEY INFORMANT INTERVIEW CONTACT SUMMARY SHEET  
 
Key Informant & Focus Group Interview Contact Summary Sheet 
 
Interview Date:________________  Interview Length:    ________________ 
 
Interview No.:  ________________  Interview Location: ________________ 
 
 
1. Physical description/impressions: 
 
 
 
 
 
 
2. Main themes and issues: 
 
 
 
 
 
 
3. Research question most directly addressed: 
 
 
 
 
 
 
4. New working hypothesis or speculations: 
 
 
 
 
 
 
5. Problems or questions: 
 
 
 
 
 
 
6. Direction of information needed for next interview: 
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APPENDIX E: HEPATITIS C POSITIVE PARTICIPANT INFORMED CONSENT 
TITLE: Examining the Impact of Hepatitis C in Montana: A Descriptive Case Study 
 
SPONSOR 
The Montana Department of Public Health and Human Services – HIV/STD/HCV Prevention 
Section 
 
STUDY DIRECTOR: 
Dr. Annie Sondag 
The University of Montana    
Department of Health & Human Performance  
Missoula, MT 59812                          
(406) 243-5215 
annie.sondag@mso.umt.edu 
 
SPECIAL INSTRUCTIONS 
The language in this consent form may be new to you.  If you read any words that are not clear to 
you, please ask the person who gave you this form to explain them to you. 
 
PURPOSE: 
Researchers at The University of Montana are working with the Montana Department of Public 
Health and Human Services (STD/HIV/HCV Section) to gather information about hepatitis C in 
Montana.  They hope that by seeking input from people living with hepatitis C they can begin to 
fill gaps in information by compiling Montana specific information about the physical and 
emotional effects of hepatitis C diagnosis and treatment, barriers to prevention and treatment, 
and current available resources to those presently infected with hepatitis C. The Montana 
Department of Public Health and Human Services (MTDPHHS) and local health departments 
will use information from this study to help increase awareness of how hepatitis C impacts 
Montana residents.  Information from this study could lead to better and more optimally targeted 
prevention and treatment efforts.  
 
PROCEDURES 
Summary report review for this study is voluntary.  You are asked to read this consent form.  If 
you agree to participate in the summary report review, you will be asked to read the report that 
highlights the major findings. There are five sections and you will be asked to answer two short 
questions about each section for a total of ten questions. This process should take roughly 60 
minutes or less. 
 
PAYMENT FOR PARTICIPATION 
You will receive $30 in exchange for your summary report.  
 
RISKS/DISCOMFORTS 
You may feel you do not know the answer or some of the questions may make you feel 
uncomfortable. You are welcome to refrain from answering any question for any reason or to 
discontinue your participation at any time. 
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BENEFITS 
Your help with this study will provide valuable information to the Montana Department of 
Public Health and Human Services.  By participating in this study, your answers will help staff 
offer services and develop programs to prevent future spreading of hepatitis C and improve the 
lives of those already infected with hepatitis C.  
 
CONFIDENTIALITY  
All information collected from your summary report review will be confidential.  Researchers 
will not use your name or any other identifying information in reports or any other materials 
related to this study.  Specifically: 
o The identities of all interview participants will remain confidential and will not be 
associated with research findings in any way. 
o At the conclusion of the study, any and all data containing information about participants 
will be destroyed. 
 
COMPENSATION FOR INJURY 
The study team believes the risk of taking part in this study is minimal.  However, the following 
liability statement is required in all University of Montana consent forms: 
 
 In the event that you are injured as a result of this research you should individually 
seek appropriate medical treatment.  If the injury is caused by the negligence of the 
University or any of its employees, you may be entitled to reimbursement by the 
department of Administration under the authority of MCA, Title 2, Chapter 9.  In 
the event of a claim of such injury, further information may be obtained from the 
University’s claims Representative or University Legal Counsel.   
 
VOLUNTEER PARTICPATION/WITHDRAWAL 
Your decision to take part in this research study is entirely voluntary.  You are free to 
NOT answer any question and to discontinue participation at any time.  You also may 
withdraw from this study for any reason.   
 
QUESTIONS 
If you have any questions about the research now or later, you may contact Dr. Annie 
Sondag at (406) 243-5215 or Annie’s Research Assistant, Blair Snyder, at (650) 823-
1786. 
 
If you have any questions regarding your rights as a research subject, you may contact the Chair 
of the IRB through The University of Montana Research Office at 243-6670. 
 
CONSENT 
I have read the above description of this study.  I have been informed of the risks and benefits 
involved, and all of my questions have been answered to my satisfaction.  Furthermore, I have 
been assured that any future questions I may have will be answered by a member of the study 
team.  I voluntarily agree to take part in this study.  I am at least 18 years old.  I understand this 
is my copy of this consent to keep. 
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APPENDIX F: SUMMARY REPORT INSTRUCTIONS 
	  
PLEASE HELP US GAIN A BETTER UNDERSTANDING ABOUT HEPATITIS C IN MONTANA 
 
 
Dear Participant, 
 
Thank you for taking the time to participate in this study. The purpose of 
this study is to fill gaps in information about hepatitis C (HCV) in Montana.  
 
Information contained in this report was obtained through a review of 
literature about HCV and through interviews with 8 professionals (also 
called key informants) throughout the state who work with people who are 
living with HCV.  
 
 
Instructions: 
Your participation is entirely voluntary. The report you will be reviewing consists of 5 
sections. We are asking you to carefully read each section and then answer the two 
questions at the end. Feel free to write as little or as much as you like in response to the 
questions in the report. However, the more fully you answer, the more help your responses 
will be to organizations who do hepatitis C prevention and treatment work. After reading 
and commenting on the review, please fill out the optional demographic form attached to 
the end of this document. When you are finished, please place the report in the envelope 
provided and drop it in the mail. 
 
This is a completely anonymous questionnaire. Do not put your name anywhere on these 
forms. Only the researchers from The University of Montana conducting this study will 
have access to your responses. No personal information will be disclosed or appear in any 
report. 
 
 
 
The results of this study will be reported to The Montana Department of Public Health and 
Human Services (DPHHS) and will be used to help DPHHS become more aware of how HCV 
impacts Montana residents. Your participation is greatly appreciated and valued. 
 
 
Sincerely, 
 
Annie Sondag, Study Director   Blair Snyder, Research Assistant 
The University of Montana    The University of Montana 
Phone: 406-243-5215     Phone: 650-823-1786 
E-Mail: annie.sondag@umontana.edu  E-Mail: blair.r.snyder@gmail.com 
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APPENDIX G: SUMMARY REPORT DEMOGRAPHIC FORM	  
Demographic Information Form (Optional)	  
Instructions:  The questions below are optional.  If you chose not to complete this demographic 
form, please leave this page blank and return the report in the envelope provided.	  
Purpose:  Completing this form will help us know if we have feedback from a variety of people. 
It is our hope that the feedback we receive from people living with hepatitis C represents a wide 
range of individuals in Montana.  We hope that we hear from men as well as women.  We hope 
to hear from people in various age groups.  We hope to hear from people living in rural as well 
as more urban areas.	  
1. Sex: [  ] Male    [  ] Female	  
2. Age: [  ] 18-24    [  ] 25-34    [  ] 35-44    [  ] 45-54    [  ] 55-64    [  ] 65-74    [  ] 75 or older	  
3. Annual Income Level: [  ] less than 6,000    [  ] 6,000-10,000    [  ] 10,001-20,000    	  
      [  ] 20,001-35,000   [  ] 35,001-50,000     [  ] 50,001-75,000    [  ] 75,001-100,000    	  
      [  ] 100,001 or more	  
4. Region of the State (please check one):	  
 [  ] Region I (1)     [  ] Region II (2)     [  ] Region III (3)    [  ] Region IV (4)    [  ] Region V 
(5)	  
  	  
	  
THANK YOU FOR HELPING US LEARN MORE ABOUT HOW HEPATITIS C 
IMPACTS MONTANANS! 
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APPENDIX H: RECRUITMENT SCRIPT FOR HCV POSITIVE PARTICIPANTS 
Verbal Instructions for Recruiting Volunteers to Review a Summary of Study Findings 
Provide each potential volunteer with an explanation of their role in reviewing the 
summary report and a brief explanation of the procedures for participating in the study. 
 
Purpose:   
Researchers at The University of Montana are working with the Montana Department of Public 
Health and Human Services (STD/HIV/HCV Section) to gather information about hepatitis C in 
Montana.  They hope that by seeking input from people living with hepatitis C they can begin to 
fill gaps in information by compiling Montana specific information about the physical and 
emotional effects of hepatitis C diagnosis and treatment, barriers to prevention and treatment, 
and current available resources to those presently infected with hepatitis C. The Montana 
Department of Public Health and Human Services (MTDPHHS) and local health departments 
will use information from this study to help increase awareness of how hepatitis C impacts 
Montana residents.  Information from this study could lead to better and more optimally targeted 
prevention and treatment efforts.  
 
Please remind them: 
• The study is completely voluntary and confidential and they may choose not to answer 
any of the questions posed in the report. 
 
• If they volunteer they will be mailed a summary report and asked to provide written 
feedback based on their experience of being infected with hepatitis C.  Specifically, after 
reading each section of the report the volunteer will be asked to respond to the following 
questions:  
1. From your perspective, does this section of the report accurately reflect your 
knowledge and experience regarding (specific section)? Why or why not? 
2. Are there any changes you would like to make to this section?  
 
• A self-addressed stamped envelope will be provided for them to return their report.  $30 
will be included with the summary report as a thank you for their participation. 
 
• No identifying information will be used from the summary report. 
 
• By participating they are helping fight the spread of hepatitis C in Montana.  The 
information gathered by the interview will be used to improve hepatitis C prevention and 
treatment programs in Montana. 
 
If individuals are willing to participate, give them a copy of the study description and the 
researcher’s contact information.  Ask them to contact the researcher at their earliest 
convenience. Allow a few minutes for potential participants to ask any question or talk it 
over. 
